Gardnerella Endolysin Intravaginal Formulations
A Gardnerella-specific endolysin formulation with polyacrylic acid polymer effectively treats bacterial vaginosis by enhancing bactericidal activity against Gardnerella biofilms and associated pathogens, addressing treatment inadequacies and recurrence issues.
Patent Information
- Application Number
- BR112025024263
- Authority / Receiving Office
- BR · BR
- Patent Type
- Applications
- Publication Date
- 2026-11-10
AI Technical Summary
Current treatments for bacterial vaginosis, particularly those targeting Gardnerella species, are inadequate due to biofilm resistance and high recurrence rates, and existing antibiotics fail to effectively eradicate Gardnerella infections, leading to ecological imbalances and increased risk of secondary infections.
A pharmaceutical composition comprising a Gardnerella-specific endolysin as the active agent and a polyacrylic acid polymer as the excipient, which enhances the lethal activity of the endolysin against Gardnerella biofilms and associated pathogens while sparing beneficial vaginal bacteria.
The composition demonstrates superior lethal activity against Gardnerella species and associated pathogens, reducing recurrence and maintaining vaginal microbiome balance, even against antibiotic-resistant strains.
Description
1 / 97 Gardnerella Endolysin Intravaginal Formulations
[001] The present invention relates to novel pharmaceutical compositions for the treatment of infections caused by bacteria of the genus Gardnerella. The pharmaceutical compositions of the invention are distinguished by comprising a Gardnerella-specific polypeptide as the active agent and a polyacrylic acid polymer as an excipient. The present invention further relates to medical uses of the pharmaceutical composition of the invention, as well as to methods of treatment using the same. FUNDAMENTALS
[002] Bacterial vaginosis (BV), also referred to in the literature as bacterial vaginosis, nonspecific vaginosis, and nonspecific vaginitis, is the most common vaginal infection worldwide and is associated with significant adverse consequences, including premature labor and delivery, postpartum endometritis, and an increased risk of HIV infection. It is a dysbiosis of the vagina in which commensal lactobacilli are displaced by a polymicrobial biofilm, the pH increases from the natural pH of 3.5-4.5 to 5.5, and a foul-smelling fluid forms. Reported prevalence rates range from 10 to 40%, depending on the population studied. However, less-than-ideal diagnostic methods and a high percentage of asymptomatic patients make it difficult to determine the true prevalence of BV. Petition 870250101940, dated 07 / 11 / 2025, p. 76 / 190 2 / 97 Gardnerella vaginalis (G. vaginalis) is a bacterial species associated with bacterial vaginosis (BV).
[003] The etiopathogenesis of BV remains poorly understood. It is most commonly defined as a pathological state characterized by the loss of normal vaginal flora, particularly of H2O2-producing Lactobacillus species, and by the simultaneous overgrowth of anaerobic bacteria, including G. vaginalis, Mobiluncus species, and Mycoplasma hominis. Recent data, however, suggest a primary role for G. vaginalis as a specific and sexually transmitted etiological agent in BV (Muzny et al., 2016, J. of Infect. Dis. 214 Suppl. 1., S1).
[004] In the 1950s, abundant small, pleomorphic, Gram-variable rods were observed in the genital tract of women with BV. This organism, initially called Haemophilus vaginalis and repeatedly renamed as more information about its characteristics became available, is now classified as G. vaginalis, which, until 2018, was considered the only member of the genus Gardnerella. However, in early 2019, it was demonstrated that the genus Gardnerella actually contains at least 13 species, and the most frequent were renamed G. vaginalis sensu stricto, G. leopoldii, G. piotii, and G. swidsinskii (Vaneechoutte et al., 2019 Int. J. Syst. Evol. Biol. 898661). Petition 870250101940, dated 07 / 11 / 2025, page 77 / 190 3 / 97
[005] Bacteria of the genus Gardnerella are special because they are Gram-variable, meaning they do not form the outer membrane that defines Gram-negative species. The cell wall is generally very thin and has only 10% or less peptidoglycan, which is why the crystal violet dye used in Gram staining does not always produce the intense purple coloration typical of Gram-positive species. Instead, Gardnerella cells can appear both Gram-positive and Gram-negative in Gram staining. Phylogenetic analysis based on 16S rRNA places Gardnerella in the family of Gram-positive bacteria Bifidobacteriales.
[006] During BV, the epithelial surface is covered by a dense collection of G. vaginalis in a biofilm that is often resistant to treatment. Biofilms are adherent communities of microorganisms held together by a polymeric matrix composed of polysaccharides, proteins, and / or nucleic acids. The distinct pattern of gene expression, as well as the physical structure of biofilms, increases bacterial resistance to various negative stimuli, including chemical disinfectants, extreme pH, host immune defenses, and antibiotics. The standard treatment for BV is the antibiotics Metronidazole and Clindamycin, which, however, frequently fail to eradicate the biofilm, so that recurrence rates reach 60% in 6 months. In addition, treatment with Petition 870250101940, dated 07 / 11 / 2025, page 78 / 190 4 / 97 antibiotics eliminate the vaginal microbiome, although they leave some viable biofilm remnants, which opens this ecological niche to other pathogens, such as fungi. Therefore, a frequent side effect of BV treatments is candidiasis. BV treatment has also been attempted with probiotics, specifically with beneficial lactobacilli that supposedly recolonize the vagina. However, several clinical trials have not demonstrated any benefit.
[007] Endolysins are promising alternatives to current antibiotics due to their ability to eradicate biofilms, their low propensity for resistance development, and their specificity for individual genera or species of bacteria. Gardnerella-specific endolysins, both natural and genetically modified, have been described (WO 2020 / 225335 A1, Landlinger et al., (2021, Pathogens 10, 1-19), or WO 2020 / 229802 A1). WO 2020 / 225335 describes recombinant Gardnerella-specific endolysins (e.g., H2B10) for use in a treatment method for Gardnerella infection, such as BV, where the bacterial vaginosis is caused by Gardnerella vaginalis sensu stricto, Gardnerella leopoldii, Gardnerella piotii, and / or Gardnerella swidsinskii. Examples 6 and 7 of document WO 2020 / 225335 demonstrate that, for example, endolysin H2B10 (as a representative of recombinant endolysins specific for Gardnerella) is superior to Petition 870250101940, dated 07 / 11 / 2025, page 79 / 190 5 / 97 antibiotics Metronidazole and Clindamycin, particularly in terms of minimum inhibitory concentration (MIC) on the suspension growth of Gardnerella strains. The results of document WO 2020 / 225335 therefore document that Gardnerella-specific (recombinant) endolysins are superior to antibiotics in the treatment of BV in general. In other words, Gardnerella-specific (recombinant) endolysins have been shown to be generally more effective in the suspension growth of Gardnerella strains, as can be deduced from the generally lower MIC values of endolysins in different Gardnerella species compared to those of antibiotics.
[008] Despite these recent advances, there is still a need in the art for compositions and / or formulations that allow for even more effective treatment of infections caused by Gardnerella species. The technical problem underlying the present invention can therefore be formulated as the provision of improved pharmaceutical compositions for the treatment of infections caused by bacteria of the genus Gardnerella.
[009] The technical problem is solved by providing the modalities and claims presented here. SUMMARY OF THE INVENTION
[0010] The present invention relates, inter alia, to Petition 870250101940, dated 07 / 11 / 2025, p. 80 / 190 6 / 97 following modalities: 1. A pharmaceutical composition comprising an effective amount of an active agent and a pharmaceutically acceptable excipient, wherein said active agent is a polypeptide with lethal activity against Gardnerella and wherein said excipient is a polyacrylic acid polymer. 2. The pharmaceutical composition according to embodiment 1, in which the aforementioned polypeptide is an endolysin with lethal activity against Gardnerella. 3. The pharmaceutical composition according to embodiment 2, wherein said endolysin comprises or consists of (i) an N-terminal catalytic domain, or a functional variant thereof; (ii) a C-terminal cell wall binding region, or a functional variant thereof, wherein the C-terminal cell wall binding region comprises or consists of at least one cell wall binding domain; and (iii) optionally a binding region between the N-terminal catalytic domain and the C-terminal cell wall binding region. 4. The pharmaceutical composition according to any of the preceding embodiments, wherein the polypeptide in question is a polypeptide with at least 80% sequence identity to the amino acid sequence. Petition 870250101940, dated 07 / 11 / 2025, page 81 / 190 7 / 97 as provided in SEQ ID NO: 1 or SEQ ID NO: 37 and with lethal activity against Gardnerella. 5. The pharmaceutical composition according to any of the preceding embodiments, wherein said polypeptide is a recombinant endolysin comprising the amino acid sequence as provided in SEQ ID NO: 1 or SEQ ID NO: 37. 6. The pharmaceutical composition according to any of the preceding embodiments, in which said polypeptide has lethal activity against Gardnerella vaginalis sensu stricto, Gardnerella leopoldii, Gardnerella piotii and / or Gardnerella swidsinskii, or any other species of the genus Gardnerella. 7. The pharmaceutical composition according to any of the preceding embodiments, in which the aforementioned polypeptide has lethal activity against Lactobacillus iners. 8. The pharmaceutical composition according to any of the preceding embodiments, in which the aforementioned polypeptide has no lethal activity against Lactobacilli crispatus, Lactobacilli gasseri, and / or Lactobacilli jensenii. 9. The pharmaceutical composition according to any of the preceding embodiments, in which the said excipient is present in a concentration of about 0.01% to 10%, preferably about 0.1% to 1%, more preferably about 0.2% to 0.5%, much more Petition 870250101940, dated 07 / 11 / 2025, p. 82 / 190 8 / 97 preferred by approximately 0.25% or approximately 0.35%. 10. The pharmaceutical composition according to any of the above embodiments, wherein the polyacrylic acid polymer is a cross-linked polyacrylic acid polymer or a carbomer. 11. A pharmaceutical composition according to any of the above embodiments, in which the combination of said active agent with said excipient enhances the pharmaceutical activity of said active agent. 12. The pharmaceutical composition according to any of the preceding embodiments, wherein said composition is suitable for intravaginal dispensing of the active agent. 13. A pharmaceutical composition according to any of the preceding embodiments, for use in the treatment of a bacterial infection in an individual, preferably where the bacterial infection is bacterial vaginosis. 14. The pharmaceutical composition for use according to modality 13, in which the individual has previously failed antibiotic treatment and / or in which the infectious bacteria are resistant to antibiotic treatment. 15. The pharmaceutical composition for use according to embodiment 14, in which the antibiotics mentioned are nitroimidazoles and / or clindamycin. 16. The pharmaceutical composition for use according to Petition 870250101940, dated 07 / 11 / 2025, page 83 / 190 9 / 97 modality 14 or 15, in which the antibiotics are Metronidazole, Tinidazole, Secnidazole, Clindamycin or any combination thereof. 17. The pharmaceutical composition for use according to any of the modalities 13 to 16, in which the individual suffers from recurrent bacterial vaginosis, preferably when the individual has had two or more episodes of BV in 6 months or has had three or more episodes of BV in 12 months. 18. The pharmaceutical composition for use according to any of the modalities 13 to 17, in which it is to be administered locally in the vagina of a woman and / or on the glans penis, foreskin or urethral opening of a man. 19. Use of the pharmaceutical composition according to any of embodiments 1 to 12 for the manufacture of a medicament for the treatment or prevention of a bacterial infection, preferably bacterial vaginosis. 20. A method for treating or preventing a bacterial infection, preferably bacterial vaginosis, in an individual in need thereof, comprising administering to said individual a therapeutically effective amount of the pharmaceutical composition according to any one of embodiments 1 to 12.
[0011] In other words, the present invention is based on the surprising and unexpected finding that polyacrylic acid polymers can increase the lethal activity of Petition 870250101940, dated 07 / 11 / 2025, p. 84 / 190 10 / 97 bactericidal polypeptides against bacteria of the genus Gardnerella. In the appended Example 2, it was demonstrated that formulations of the bactericidal polypeptides H2B10 (PM-477) and H2B10B11 with a polyacrylic acid polymer resulted in lethal activity against Gardnerella biofilms superior to the additional lethal activity of the individual components alone, clearly indicating a synergistic mode of action.
[0012] While polyacrylic acid polymers alone exhibit some degree of lethal activity against Gardnerella biofilms (see Example 2), polyacrylic acid polymers alone do not exhibit lethal activity against planktonic Gardnerella cells (Example 4, Figure 4) and exhibit only very limited lethal activity against other pathogens associated with BV (Example 4, Figure 5). Despite this limited or absent lethal activity of polyacrylic acid polymers against planktonic bacteria, it has been surprisingly demonstrated in the appended Examples 3 and 5 (FIGs. 3 and 6) that polyacrylic acid polymers enhance the lethal activity of bactericidal polypeptides against planktonic Gardnerella species and also against other pathogens associated with bacterial vaginosis, such as Lactobacillus iners, Mobiluncus mulieris, Atopobium vaginae, and Prevotella bivia. It is worth noting that the bactericidal polypeptide alone does not present Petition 870250101940, dated 07 / 11 / 2025, page 85 / 190 11 / 97 lethal activity against other pathogens associated with bacterial vaginosis (FIG. 1B). Thus, it was surprisingly found that polyacrylic acid polymers not only improve the lethal activity of bactericidal polypeptides against Gardnerella species, but also increase the antimicrobial spectrum of bactericidal polypeptides to target other pathogens associated with bacterial vaginosis. It is worth highlighting that this surprising effect was observed for two different polyacrylic acid polymers, namely, a linear polyacrylic acid polymer and a cross-linked polyacrylic acid polymer (Carbopol 974P).
[0013] Thus, compelling evidence has been provided that the formulation of bactericidal polypeptides, in particular bactericidal polypeptides specific for Gardnerella, with a polyacrylic acid polymer can significantly increase the lethal activity of the bactericidal polypeptide against Gardnerella species and other bacteria associated with BV.
[0014] Consequently, in a specific embodiment, the invention relates to a pharmaceutical composition comprising an effective amount of an active agent and a pharmaceutically acceptable excipient, wherein said active agent is a polypeptide with lethal activity against Gardnerella and wherein said excipient is a polyacrylic acid polymer. Petition 870250101940, dated 07 / 11 / 2025, p. 86 / 190 12 / 97
[0015] The active agent comprised in the pharmaceutical composition of the present invention is, preferably, a bactericidal polypeptide specific to the genus Gardnerella, that is, specifically targeting bacteria belonging to the genus Gardnerella. The polypeptide comprised in the pharmaceutical composition of the present invention therefore preferably has lethal activity against species of the genus Gardnerella. For example, the polypeptide comprised in the pharmaceutical composition of the present invention may have lethal activity against Gardnerella vaginalis sensu stricto, Gardnerella leopoldii, Gardnerella piotii and / or Gardnerella swidsinskii, preferably against all of them. The lethal activity of the polypeptide comprised in the pharmaceutical composition of the present invention against Gardnerella is, more preferably, a genus-selective lethal activity against Gardnerella.
[0016] Here, “genus-selective lethal activity” or “genus-specific bacteriolytic effect” means that the polypeptide comprised in the pharmaceutical composition of this invention does not have lethal activity or a bacteriolytic effect against bacteria in general. Preferably, the polypeptide comprised in the pharmaceutical composition of the present invention has genus-selective lethal activity against Gardnerella, but not against Petition 870250101940, dated 07 / 11 / 2025, p. 87 / 190 13 / 97 Lactobacilli crispatus, Lactobacilli gasseri, and / or Lactobacilli jensenii. More preferably, the aforementioned polypeptide does not have lethal activity against all of these Lactobacilli, namely, Lactobacilli crispatus, Lactobacilli gasseri, and Lactobacilli jensenii.
[0017] Those skilled in the art will understand that the term genus-selective lethal activity should not be understood in the strictest sense, given the enormous diversity of bacteria and the uncertain boundaries between different species and genera. For example, the species Lactobacillus iners is classified as a species of the genus Lactobacillus, although it differs significantly from other species of the genus Lactobacillus, such as Lactobacillus crispatus, which encodes more than twice as many proteins as Lactobacillus iners (see France et al., Applied and Environmental Microbiology. 82 (24): 7063-7073). Therefore, it should be understood that an endolysin with genus-selective lethal activity may have lytic activity against bacterial species of other genera, but, preferably, does not have lethal activity against most bacteria.
[0018] In certain embodiments, the polypeptide comprised in the pharmaceutical composition of the present invention may have lethal activity against other pathogens associated with VB. That is, in certain embodiments, the polypeptide comprised in the pharmaceutical composition of the present invention Petition 870250101940, dated 07 / 11 / 2025, p. 88 / 190 14 / 97 may have lethal activity against one or more of the following types of Lactobacillus iners, Mobiluncus mulieris, Atopobium vaginae, and / or Prevotella bivia, particularly when formulated with a polyacrylic acid polymer. In certain embodiments, the polypeptide comprised in the pharmaceutical composition of the present invention may have lethal activity against all types of Lactobacillus iners, Mobiluncus mulieris, Atopobium vaginae, and Prevotella bivia, particularly when formulated with a polyacrylic acid polymer.
[0019] As used herein, the “lethal activity” of an active agent, such as a bactericidal polypeptide, against specific bacteria may be defined as a reduction in the number of viable bacterial cells caused by the activity of said active agent. The lethal activity of the active agent against said bacteria may be complete, meaning that 100% of the bacterial cells were eliminated, or partial, meaning that at least about 80%, at least about 90%, at least about 95%, at least about 99%, or at least about 99.9% of the bacterial cells were eliminated. The lethal activity of an active agent on a specific microorganism may be determined by standard field procedures, including those based on the determination of the Minimum Inhibitory Concentrations (MICs) of an antimicrobial agent, defined as Petition 870250101940, dated 07 / 11 / 2025, page 89 / 190 15 / 97 the lowest concentration of the aforementioned antimicrobial agent that inhibits the visible growth of a microorganism after overnight incubation, as described in Andrews, 2001, J Antimicrobial Chemotherapy, 48, Suppl. SI, 5-16 or in Document M7-A7, “Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standards, 7th Edition, January 2006, vol. 26, No. 2” published by the Clinical and Laboratory Standards Institute. Another suitable method for determining the lethal activity of an active agent is described in the examples section of document WO 2020 / 225335 and consists of measuring a decrease in optical density at 610-620 nm of a bacterial cell suspension and / or a decrease in Colony Forming Units (CFU) per milliliter of a bacterial cell suspension after exposure to the active agent to be tested.The decrease in Optical Density measured at 610-620 nm of a bacterial suspension, whose susceptibility is to be tested, can be determined in an in vitro turbidity assay performed in the presence of the active agent. According to another embodiment, in an in vitro turbidity test, an active agent exhibits lethal activity against Gardnerella when said active agent decreases the OD(610-620 nm) of a suspension of at least one strain of Gardnerella bacteria by more than 20%, more than 30%, more than 40%, more than 50%, more than 60%, more than 70%, more than 80%, more than 90%, or more than 95%. Petition 870250101940, dated 07 / 11 / 2025, pp. 90 / 190 16 / 97
[0020] The polypeptide comprised in the pharmaceutical composition of the present invention additionally has, in a preferred manner, lethal activity against antibiotic-resistant Gardnerella strains, as described in more detail below. In a preferred embodiment, the polypeptide comprised in the pharmaceutical composition of the present invention has lethal activity against Gardnerella strains resistant to one or more antibiotics selected from the group consisting of nitroimidazoles and clindamycin. In a more preferred embodiment, the polypeptide comprised in the pharmaceutical composition of the present invention has lethal activity against Gardnerella strains resistant to Metronidazole, Tinidazole, Secnidazole, Clindamycin, or any combination thereof. In a still more preferred embodiment, the polypeptide comprised in the pharmaceutical composition of the present invention has lethal activity against Gardnerella strains resistant to Metronidazole and / or Clindamycin.In an even more preferred embodiment, the polypeptide comprised in the pharmaceutical composition of the present invention has lethal activity against Gardnerella strains resistant to Metronidazole. In an even more preferred embodiment, the polypeptide comprised in the pharmaceutical composition of the present invention has lethal activity against Gardnerella strains highly resistant to the antibiotics mentioned above. Petition 870250101940, dated 07 / 11 / 2025, page 91 / 190 17 / 97
[0021] The bactericidal polypeptide comprised in the pharmaceutical composition according to the invention may be any polypeptide that has lethal activity against one or more species of Gardnerella. Thus, in a specific embodiment, the invention relates to the pharmaceutical composition according to the invention, in which said polypeptide has lethal activity against Gardnerella vaginalis sensu stricto, Gardnerella leopoldii, Gardnerella piotii and / or Gardnerella swidsinskii, or any other species of the genus Gardnerella. Means and methods for analyzing whether a given polypeptide has lethal activity against Gardnerella species are provided herein and are known to those skilled in the art.
[0022] The pharmaceutical composition according to the invention is preferably used in the treatment of bacterial vaginosis. In certain embodiments, the pharmaceutical composition may be effective in eliminating other bacteria associated with bacterial vaginosis, such as Lactobacillus iners, Atopobium vaginae, Prevotella bivia, Mubiluncus mulieris, Mubiluncus curtisii, and Streptococcus agalactiae, particularly when the pharmaceutical composition comprises a polyacrylic acid polymer. Thus, in a particular embodiment, the invention relates to the pharmaceutical composition according to the invention, in which said polypeptide has lethal activity against Lactobacillus iners, Petition 870250101940, dated 07 / 11 / 2025, p. 92 / 190 18 / 97 Atopobium vaginae, Prevotella bivia, Mubiluncus mulieris, Mubiluncus curtisii, and / or Streptococcus agalactiae, particularly when formulated with a polyacrylic acid polymer.
[0023] Although it is preferable that the polypeptide contained in the pharmaceutical composition of the invention have lethal activity against Gardnerella species and other pathogens associated with BV, it is important that the polypeptide contained in the pharmaceutical composition of the invention have no lethal activity, or essentially no lethal activity, against commensal vaginal bacteria. Commensal vaginal bacteria are important for maintaining a normal vaginal flora and include, among others, Lactobacilli crispatus, Lactobacilli gasseri, and Lactobacilli jensenii. It has been demonstrated in the attached Example 3 that the bactericidal polypeptide H2B10 (PM-477) and in the attached Example 5 that the bactericidal polypeptide H2B10B11 has no lethal activity against the commensal vaginal bacterium Lactobacilli crispatus, which is one of the most prevalent bacteria in a healthy vaginal microbiota.Thus, in one specific embodiment, the invention relates to the pharmaceutical composition according to the invention, wherein said polypeptide has no lethal activity against Lactobacilli crispatus, Lactobacilli gasseri, and / or Lactobacilli jensenii. In certain embodiments, the invention relates to the pharmaceutical composition according to... Petition 870250101940, dated 07 / 11 / 2025, p. 93 / 190 19 / 97 the invention, in which the said polypeptide has lethal activity against Lactobacillus iners, but does not have lethal activity against Lactobacilli crispatus, Lactobacilli gasseri, and / or Lactobacilli jensenii.
[0024] That is, in certain embodiments, the polypeptide comprised in the pharmaceutical composition of the invention is an endolysin with selective killing activity against Gardnerella vaginalis sensu stricto and at least one of Gardnerella leopoldii, Gardnerella piotii, Gardnerella swidsinskii, Lactobacillus iners, Atopobium vaginae, Prevotella bivia, Mubiluncus mulieris, Mubiluncus curtisii, and / or Streptococcus agalactiae; wherein the endolysin has no lethal activity, or essentially no lethal activity, against at least one of Lactobacilli crispatus, Lactobacilli gasseri, and / or Lactobacilli jensenii.
[0025] The terms peptide, polypeptide, “protein” and variations of these terms refer to peptides, oligopeptides, oligomers or proteins, including fusion proteins, comprising at least two amino acids linked together by a normal or modified peptide bond, as in the case of isosteric peptides, for example. These terms also include peptidomimetics, which are defined as peptide analogs containing non-peptidic structural elements, whose peptides are capable of mimicking or antagonizing the biological action(s) of a Petition 870250101940, dated 07 / 11 / 2025, page 94 / 190 20 / 97 original natural peptide. A peptidomimetic does not have classic peptide characteristics, such as enzymatically cleaved peptide bonds. A peptide or polypeptide may be composed of amino acids other than the 20 amino acids defined by the genetic code. It may be composed of L-amino acids and / or D-amino acids. A peptide or polypeptide may also be composed of amino acids modified by natural processes, such as post-translational maturation processes, or by chemical processes, which are well known to one skilled in the art. Such modifications are extensively detailed in the literature. These modifications may appear anywhere in the polypeptide: in the peptide backbone, in the amino acid chain, or even at the carboxy or amino-terminal ends. A peptide or polypeptide may be branched after ubiquitination or be cyclic with or without branching.This type of modification can result from natural or synthetic post-translational processes, which are well known to one skilled in the art. For example, modifications of peptides or polypeptides may include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, covalent or non-covalent crosslinking, cyclization, disulfide bond formation, demethylation, etc. Petition 870250101940, dated 07 / 11 / 2025, page 95 / 190 21 / 97 Glycosylation including pegylation, hydroxylation, iodization, methylation, myristoylation, oxidation, proteolytic processes, phosphorylation, prenylation, racemization, seneloylation, sulfation, addition of amino acids, such as arginylation or ubiquitination. Such modifications are fully detailed in the literature and well known to those skilled in the art.
[0026] In preferred embodiments of the present invention, the polypeptide comprised in the pharmaceutical composition according to the invention is an endolysin. Thus, in a specific embodiment, the invention relates to the pharmaceutical composition according to the invention, in which said polypeptide is an endolysin with lethal activity against Gardnerella.
[0027] The term “endolysin,” as used in this document, refers to a polypeptide generally produced by bacteriophages to digest the cell wall of the host bacterium and release bacteriophage progeny. An endolysin is a cell wall-lytic enzyme encoded by bacteriophages that has the ability to hydrolyze the cell wall of target bacteria when added exogenously (lysis from the outside in). This new class of antibacterials presents important advantages over classic antibiotics, such as a novel mode of action; a narrow spectrum of susceptible bacteria; rapid elimination of stationary bacteria and in Petition 870250101940, dated 07 / 11 / 2025, page 96 / 190 22 / 97 exponential growth; activity in mucous membranes and bacterial biofilms; low probability of resistance development; and reduced impact on normal microbiota. These unique characteristics have driven interest in the biotechnological and pharmacological exploration of lysins and their recent inclusion among the main current alternatives to combat antibiotic resistance.
[0028] Endolysins generally consist of two or more domains: at least one catalytic domain, such as a hydrolase domain (typically located at the N-terminal of the polypeptide), which cleaves specific motifs in the peptidoglycan layer, and often one or more cell wall-binding domains (classically located at the C-terminal of the polypeptide), which are involved in specific binding and processing of bacterial peptidoglycan. While providing a general organization for endolysin structure, this typical architecture is not a defining characteristic of all endolysins. Endolysins from Gram-positive bacteria and their phages generally comprise at least one catalytic domain and one or more cell wall-binding domains. In contrast, many endolysins produced by Gram-negative species or their phages contain only the catalytic domain, although modular endolysins have also been reported. The catalytic units Petition 870250101940, dated 07 / 11 / 2025, page 97 / 190 23 / 97 determine the type of peptidoglycan (PG) bond to be cleaved, while the cell wall binding domain(s) largely determine(s) the lytic spectrum through specific recognition of cell wall elements distributed in a genus- or species / strain-specific manner.
[0029] The endolysin comprised in the pharmaceutical composition of the present invention is, preferably, a functional polypeptide, whose function comprises specifically targeting bacteria of the genus Gardnerella, more preferably eliminating bacteria of the genus Gardnerella. The endolysin comprised in the pharmaceutical composition of the present invention further comprises, preferably, a catalytic domain or a functional fragment thereof and / or a cell wall binding domain or a functional fragment thereof. The endolysin comprised in the pharmaceutical composition of the present invention may be a natural or recombinant endolysin. The endolysin comprised in the pharmaceutical composition of the present invention is, more preferably, a recombinant endolysin.The endolysin comprised in the pharmaceutical composition of the present invention is, more preferably, a recombinant endolysin comprising or consisting of (i) an N-terminal catalytic domain, or a variant. Petition 870250101940, dated 07 / 11 / 2025, page 98 / 190 24 / 97 functional of the same; (ii) a C-terminal cell wall binding region, or a functional variant thereof, wherein the C-terminal cell wall binding region comprises or consists of at least one cell wall binding domain; and (iii) optionally a binding region between the N-terminal catalytic domain and the C-terminal cell wall binding region, and preferably has lethal activity, more preferably selective lethal activity to the genus, against Gardnerella cells / strains.
[0030] As defined herein, the terms binding and “binding to,” referring to the ability of an endolysin to bind to the cell wall of a specific bacterium, refer to the ability of said endolysin to specifically interact with and adhere to the cell wall of said bacterium. The ability of an endolysin to bind to the cell wall of a bacterium can be determined by methods known in the art.
[0031] In the context of the present description, the term “recombinant endolysin” preferably refers to an endolysin that has undergone domain switching, as defined in WO 2020 / 225335. In accordance with this definition, those skilled in the art will readily understand that “domain-switched” or “recombinant” endolysins Petition 870250101940, dated 07 / 11 / 2025, page 99 / 190 25 / 97 as described herein, are endolysins that do not occur naturally. That is, the recombinant endolysin for use in the present invention has been manually modified and excludes, by definition, natural endolysins, i.e., those that can be found naturally in nature. The accompanying examples, as well as the teachings of document WO 2020 / 225335, provide suitable method(s) for generating the artificial endolysin of the invention.
[0032] The term “catalytic domain” or “enzymatic domain” refers to the part of the protein chain that contains the region where the catalyzed chemical reaction occurs. The “catalytic domain,” as used herein, refers to a functional polypeptide whose function comprises the ability to lyse the cell wall of Gardnerella. In particular, the catalytic domain, as described herein, may preferably modify and / or cleave a substrate in the cell walls of Gardnerella, preferably a peptidoglycan. Preferably, the catalytic domain cleaves the peptidoglycan in the cell walls of Gardnerella and may cause Gardnerella cell lysis. Preferably, the catalytic domain may modify and / or cleave bonds present in the cell wall and / or peptidoglycan of Gardnerella spp., such as Gardnerella vaginalis sensu stricto, Gardnerella leopoldii, Gardnerella piotii, and / or Gardnerella swidsinskii, preferably all of them. Petition 870250101940, dated 07 / 11 / 2025, pp. 100 / 190 26 / 97 Ideally, the catalytic domain does not modify and / or cleave a substrate, preferably peptidoglycan, present in the cell wall of bacteria other than Gardnerella spp., preferably healthy vaginal commensal bacteria such as Lactobacillus spp., including Lactobacillus crispatus, Lactobacilli gasseri, and / or Lactobacilli jensenii. The catalytic domain may be an N-acetylmuramise, N-acetylmuramyl-L-alanine amidase, L-alanoyl-D-glutamate endopeptidases, interpeptide bridge endopeptidases, or N-acetyl-beta-D-glucosaminidases. Preferably, the N-terminal catalytic domain is an N-acetylmuramise, more preferably a 1,4-beta-N-acetylmuramise. The catalytic domain is preferably located in the N-terminal region of (recombinant) endolysin, and is therefore called the "N-terminal catalytic domain".Even more preferably, the N-terminal catalytic domain is located in the N-terminal region of the C-terminal cell wall-binding region within the (recombinant) endolysin.
[0033] The endolysin contained in the pharmaceutical composition of the present invention preferably comprises a catalytic domain consisting of a polypeptide comprising or consisting of the amino acid sequence of any of the SEQ ID NOs: 2 to 10 or any functional variant thereof with at least 80% identity with the Petition 870250101940, dated 07 / 11 / 2025, pp. 101 / 190 27 / 97 amino acid sequence of any of the SEQ ID NOs: 2 to 10. As demonstrated in document WO 2020 / 225335, the most active catalytic domain is H2 (SEQ ID NO: 3).Consequently, in a preferred aspect of the present invention, the catalytic domain consists of a polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 3, or any functional variant thereof, with at least 80% identity (preferably at least 85% identity, more preferably at least 90% identity, even more preferably at least 95% identity, even more preferably at least 96% identity, even more preferably at least 97% identity, even more preferably at least 98% identity, even more preferably at least 99% identity, even more preferably at least 99.5% identity and even more preferably at least 99.7% identity) with the amino acid sequence of SEQ ID NO: 3, wherein the endolysin is functional, wherein the function comprises the ability to lyse the Gardnerella cell wall.The catalytic domain is preferably located in the N-terminal region of the (recombinant) endolysin, and is therefore called the N-terminal catalytic domain. Even more preferably, the (recombinant) endolysin further comprises a cell wall-binding region and the N-terminal catalytic domain. Petition 870250101940, dated 07 / 11 / 2025, page 102 / 190 28 / 97 is located in the N-terminal region of the C-terminal cell wall-binding region, within (recombinant) endolysin.
[0034] The “cell wall binding region,” as used in this document, refers to a functional polypeptide, wherein the function comprises the ability to bind to the cell wall of Gardnerella. The cell wall binding region may comprise or consist of one, two, three, or more cell wall binding domains. Cell wall binding domains are polypeptides that interact with and / or bind to bacterial cell walls and / or specific substrates within bacterial cell walls. In particular, the cell wall binding domain described herein may preferably bind specifically to the cell wall (e.g., peptidoglycan) of Gardnerella spp., such as Gardnerella vaginalis sensu stricto, Gardnerella leopoldii, Gardnerella piotii, and / or Gardnerella swidsinskii, preferably all of them.The cell wall binding region is preferably located in the C-terminal region within the (recombinant) endolysin, and is thus termed the “C-terminal cell wall binding region”. Even more preferably, the C-terminal cell wall binding region is located C-terminally from the N-terminal catalytic domain within the (recombinant) endolysin. Petition 870250101940, dated 07 / 11 / 2025, page 103 / 190 29 / 97
[0035] The endolysin contained in the pharmaceutical composition of the present invention preferably comprises a cell wall binding region comprising or consisting of at least one cell wall binding domain selected from the group consisting of polypeptides comprising or consisting of the amino acid sequence of any of the SEQ ID NOS: 11 to 28, and any functional variant thereof with at least 80% identity (preferably at least 85% identity, more preferably at least 90% identity, even more preferably at least 95% identity, even more preferably at least 96% identity, even more preferably at least 97% identity, even more preferably at least 98% identity, even more preferably at least 99% identity, even more preferably at least 99.5% identity and even more preferably at least 99.7% identity) with the amino acid sequence of any of the SEQ ID NOs: 11 to 28. As shown in document WO 2020 / 225335, the most active cell wall binding region is B10 (comprising the cell wall binding domains of SEQ ID NOs: 23 and 24), followed by B11 (comprising the cell wall binding domains of SEQ ID NOs: 25 and 26). Thus, in a preferred aspect of the present invention, the cell wall binding domain(s) is / are selected from the group, Petition 870250101940, dated 07 / 11 / 2025, page 104 / 190 30 / 97 consisting of polypeptides comprising or consisting of the amino acid sequence of any of the SEQ IDs NOS: 23, 24, 25 and 26, and any functional variant thereof with at least 80% identity (preferably at least 85% identity, more preferably at least 90% identity, even more preferably at least 95% identity, even more preferably at least 96% identity, even more preferably at least 97% identity, even more preferably at least 98% identity, even more preferably at least 99% identity, even more preferably at least 99.5% identity and even more preferably at least 99.7% identity) with the amino acid sequence of any of the SEQ IDs NOS: 23, 24, 25 and 26, whereby endolysin is functional, in which the The function includes the ability to lyse the cell wall of Gardnerella.The cell wall binding region is preferably located in the C-terminal region within the (recombinant) endolysin, and is thus termed the “C-terminal cell wall binding region.” Even more preferably, the (recombinant) endolysin further comprises a catalytic domain, and the catalytic domain is located in the N-terminal region of the C-terminal cell wall binding region within the (recombinant) endolysin.
[0036] Endolysin contained in the pharmaceutical composition Petition 870250101940, dated 07 / 11 / 2025, page 105 / 190 31 / 97 of the present invention preferably comprises two cell wall binding domains (within the cell wall binding region). In a preferred aspect of the present invention, the cell wall binding domains of the endolysin of the invention each consist of a polypeptide comprising or consisting of the amino acid sequence of any of the SEQ ID NOs: 23, 24, 25 and 26, and any functional variant thereof with at least 80% identity (preferably at least 85% identity, more preferably at least 90% identity, even more preferably at least 95% identity, even more preferably at least 96% identity, even more preferably at least 97% identity, even more preferably at least 98% identity, even more preferably at least 99% identity, even more preferably at least 99% identity).5% identity and, in a more preferred manner, at least 99.7% identity) with the amino acid sequence of any of the SEQ ID NOs: 23, 24, 25 and 26, whereby the endolysin is functional, wherein the function comprises the ability to lyse the cell wall of Gardnerella. In a more preferred aspect of the present invention, the endolysin comprises a first cell wall-binding domain and a second cell wall-binding domain, wherein said first cell wall-binding domain, Petition 870250101940, dated 07 / 11 / 2025, pp. 106 / 190 32 / 97 is selected from the group consisting of SEQ ID NOs: 23 and 25, and said second cell wall binding domain is selected from the group consisting of SEQ ID NOs: 24 and 26. Preferably, said first cell wall binding domain is located at the N-terminal end of said second cell wall binding domain.
[0037] In a more preferred embodiment, the endolysin comprised in the pharmaceutical composition of the present invention comprises (i) an N-terminal catalytic domain consisting of a polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 3, or any functional variant thereof, with at least 80% identity (preferably at least 85% identity, more preferably at least 90% identity, even more preferably at least 95% identity, even more preferably at least 96% identity, even more preferably at least 97% identity, even more preferably at least 98% identity, even more preferably at least 99% identity, even more preferably at least 99.5% identity and even more preferably at least 99.7% identity) with the amino acid sequence of SEQ ID NO: 3;and (ii) a C-terminal cell wall binding region comprising or consisting of a first binding domain; Petition 870250101940, dated 07 / 11 / 2025, page 107 / 190 33 / 97 to the cell wall and a second cell wall binding domain, wherein said first cell wall binding domain is selected from the group consisting of SEQ IDs 23 and 25, and any functional variant thereof with at least 80% identity (preferably at least 85% identity, more preferably at least 90% identity, even more preferably at least 95% identity, even more preferably at least 96% identity, even more preferably at least 97% identity, even more preferably at least 98% identity, even more preferably at least 99% identity, even more preferably at least 99.5% identity and even more preferably at least 99.7% identity) with the amino acid sequence of either of the SEQ IDs 23 and 25,and wherein the said second cell wall binding domain is selected from the group consisting of SEQ IDs NOS: 24 and 26 and any functional variant thereof with at least 80% identity (preferably at least 85% identity, more preferably at least 90% identity, even more preferably at least 95% identity, even more preferably at least 96% identity, even more preferably at least 97% identity, even more preferably at least, Petition 870250101940, dated 07 / 11 / 2025, pp. 108 / 190 34 / 97 98% identity, more preferably at least 99% identity, more preferably at least 99.5% identity, and more preferably at least 99.7% identity) with the amino acid sequence of any of the SEQ ID NOS: 24 and 26; through which endolysin is functional, wherein the function comprises the ability to lyse the Gardnerella cell wall. Preferably, said first cell wall binding domain is located at the N-terminal end of said second cell wall binding domain.
[0038] In a particularly preferred embodiment, the endolysin comprised in the pharmaceutical composition of the present invention comprises (i) an N-terminal catalytic domain consisting of a polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 3; and (ii) a C-terminal cell wall binding region comprising or consisting of a first cell wall binding domain and a second cell wall binding domain, wherein said first cell wall binding domain is selected from the group consisting of SEQ ID NOs: 23 and 25, and said second cell wall binding domain is selected from the group consisting of SEQ ID NOs: Petition 870250101940, dated 07 / 11 / 2025, pp. 109 / 190 35 / 97 and 26.
[0039] Preferably, said first cell wall binding domain is located at the N-terminal end of said second cell wall binding domain.
[0040] Illustrative examples of particularly preferred endolysins comprised in the pharmaceutical composition of the present invention are H2B10 (comprising from the N-terminal to the C-terminal: SEQ ID NOs: 3, 23, and 24), H2B11 (comprising from the N-terminal to the C-terminal: SEQ ID NOs: as defined in WO 2020 / 225335), and H2B10B11 (comprising from the N-terminal to the C-terminal: SEQ ID NOs: 3, 23, and 26).
[0041] The endolysin comprised in the pharmaceutical composition of the present invention further comprises, preferably, a binding region between the N-terminal catalytic domain and the C-terminal cell wall binding region. The binding region may consist of a polypeptide with a length of 6 to 18 amino acids, preferably 9 to 15 amino acids, and even more preferably 12 amino acids. Preferably, the binding region may consist of a polypeptide comprising or consisting of the amino acid sequence (i) (XXX)n, wherein each X may independently be G, A or S, preferably wherein the amino acid sequence (XXX)n Petition 870250101940, dated 07 / 11 / 2025, pp. 110 / 190 36 / 97 is (GGS)n, where n corresponds to the number of repetitions of the sequence XXX, preferably where n is 2, 3, 4, 5 or 6, or (ii) X1X2GLNGX3X4NGGS (SEQ ID NO: 36), where Xi is N or K, X2 is A or V, X3 is Y or C, and X4 is K or Q. Non-limiting examples of such linking regions are provided in SEQ ID NOs: 29 to 35.
[0042] In a specific preferred embodiment, the endolysin comprised in the pharmaceutical composition of the present invention is H2B10”, whose sequence is presented in SEQ ID NO: 1 or is H2B10B11, whose sequence is presented in SEQ ID NO: 37.
[0043] In a specific embodiment, the invention relates to the pharmaceutical composition according to the invention, wherein said polypeptide is a polypeptide with at least 80% sequence identity with the amino acid sequence as provided in SEQ ID NO: 1 and with lethal activity against Gardnerella.
[0044] That is, in certain embodiments, the invention provides a pharmaceutical composition comprising an effective amount of Gardnerella-specific endolysin, preferably a recombinant Gardnerella-specific endolysin, and a polyacrylic acid polymer, wherein said endolysin is a polypeptide with at least 80% sequence identity to the amino acid sequence as provided in SEQ ID NO: 1 and with lethal activity against Petition 870250101940, dated 07 / 11 / 2025, p. 111 / 190 37 / 97 Gardnerella. In a more preferred embodiment, the invention provides a pharmaceutical composition comprising an effective amount of Gardnerella-specific endolysin, preferably a recombinant Gardnerella-specific endolysin, and a polyacrylic acid polymer, wherein said endolysin is a polypeptide with at least 90% sequence identity to the amino acid sequence as provided in SEQ ID NO: 1 and with lethal activity against Gardnerella. In a further preferred embodiment, the invention provides a pharmaceutical composition comprising an effective amount of Gardnerella-specific endolysin, preferably a recombinant Gardnerella-specific endolysin, and a polyacrylic acid polymer, wherein said endolysin is a polypeptide with at least 95% sequence identity to the amino acid sequence as provided in SEQ ID NO: 1 and with lethal activity against Gardnerella.In an even more preferred embodiment, the invention provides a pharmaceutical composition comprising an effective amount of Gardnerella-specific endolysin, preferably a recombinant Gardnerella-specific endolysin, and a polyacrylic acid polymer, wherein said endolysin is a polypeptide with at least 99% sequence identity to the amino acid sequence as provided in SEQ ID NO: 1 and with lethal activity against. Petition 870250101940, dated 07 / 11 / 2025, p. 112 / 190 38 / 97 Gardnerella. In a much more preferred embodiment, the invention provides a pharmaceutical composition comprising an effective amount of Gardnerella-specific endolysin, preferably a recombinant Gardnerella-specific endolysin, and a polyacrylic acid polymer, wherein said endolysin comprises or consists of the amino acid sequence as provided in SEQ ID NO: 1.
[0045] Therefore, in a specific embodiment, the invention relates to the pharmaceutical composition according to the invention, wherein said polypeptide is recombinant endolysin comprising the amino acid sequence provided in SEQ ID NO: 1.
[0046] Endolysin comprising or consisting of the amino acid sequence as provided in SEQ ID NO: 37 can also be used in the context of this invention, i.e., in the context of a pharmaceutical composition suitable for the treatment of bacterial vaginosis, comprising an effective amount of Gardnerella-specific endolysin, preferably a recombinant Gardnerella-specific endolysin, and a polyacrylic acid polymer. Consequently, endolysin comprising or consisting of the amino acid sequence as provided in SEQ ID NO: 37 is an alternative to the Gardnerella-specific endolysin provided in SEQ ID NO. 1. Petition 870250101940, dated 07 / 11 / 2025, p. 113 / 190 39 / 97
[0047] Thus, in a specific embodiment, the invention relates to the pharmaceutical composition according to the invention, wherein said polypeptide is a polypeptide with at least 80% sequence identity with the amino acid sequence as provided in SEQ ID NO: 37 and with lethal activity against Gardnerella.
[0048] Thus, in certain embodiments, the invention provides a pharmaceutical composition comprising an effective amount of Gardnerella-specific endolysin, preferably a recombinant Gardnerella-specific endolysin, and a polyacrylic acid polymer, wherein said endolysin is a polypeptide with at least 80% sequence identity to the amino acid sequence as provided in SEQ ID NO: 37 and with lethal activity against Gardnerella. In a more preferred embodiment, the invention provides a pharmaceutical composition comprising an effective amount of Gardnerella-specific endolysin, preferably a recombinant Gardnerella-specific endolysin, and a polyacrylic acid polymer, wherein said endolysin is a polypeptide with at least 90% sequence identity to the amino acid sequence as provided in SEQ ID NO: 37 and with lethal activity against Gardnerella.In an even more preferred embodiment, the invention provides a pharmaceutical composition comprising an effective amount. Petition 870250101940, dated 07 / 11 / 2025, page 114 / 190 40 / 97 of Gardnerella-specific endolysin, preferably a recombinant Gardnerella-specific endolysin, and a polyacrylic acid polymer, wherein said endolysin is a polypeptide with at least 95% sequence identity to the amino acid sequence as provided in SEQ ID NO: 37 and with lethal activity against Gardnerella. In a further preferred embodiment, the invention provides a pharmaceutical composition comprising an effective amount of Gardnerella-specific endolysin, preferably a recombinant Gardnerella-specific endolysin, and a polyacrylic acid polymer, wherein said endolysin is a polypeptide with at least 99% sequence identity to the amino acid sequence as provided in SEQ ID NO: 37 and with lethal activity against Gardnerella.In a much more preferred embodiment, the invention provides a pharmaceutical composition comprising an effective amount of Gardnerella-specific endolysin, preferably recombinant Gardnerella-specific endolysin, and a polyacrylic acid polymer, wherein said endolysin comprises or consists of the amino acid sequence as provided in SEQ ID NO: 37.
[0049] Therefore, in a specific embodiment, the invention relates to the pharmaceutical composition according to the invention, wherein said polypeptide is endolysin. Petition 870250101940, dated 07 / 11 / 2025, pp. 115 / 190 41 / 97 recombinant comprising the amino acid sequence provided in SEQ ID NO: 37.
[0050] In one aspect, the invention relates to a pharmaceutical composition comprising a recombinant endolysin with at least 80% sequence identity to the amino acid sequence provided in SEQ ID NO: 1 or 37 and with lethal activity against Lactobacillus iners for use in the treatment of a bacterial infection involving and / or caused by the species Lactobacillus iners.
[0051] L. iners is a bacterial species associated with an unbalanced vaginoma and is known to be potentially relevant in cases of BV. After treatment with metronidazole (MDZ), patients frequently transition to a microbiome dominated by L. iners, followed by BV recurrence. Therefore, endolysins with (additional) lethal activity against L. iners are of particular relevance in the treatment of BV.
[0052] Preferably, the invention relates to a pharmaceutical composition comprising a recombinant endolysin comprising an amino acid sequence as provided in SEQ ID NO: 1 or 37 for use in the treatment of a bacterial infection involving and / or caused by the species Lactobacillus iners. It has been surprisingly demonstrated in Figures 1B, 3 and 6 that the endolysins PM-477 and H2B10B11 exhibit exterminating activity against L. Petition 870250101940, dated 07 / 11 / 2025, pp. 116 / 190 42 / 97 iners, both in the absence and presence of a polyacrylic acid polymer. In certain embodiments, the bacterial infection caused by L. iners is a vaginal infection, in particular bacterial vaginosis. It should be understood that any of the embodiments described herein applies equally to the composition for use in the treatment of L. iners infections. In particular, the composition may additionally comprise a polyacrylic acid polymer, as described elsewhere in this document. In certain embodiments, the invention relates to a method for treating infections involving and / or caused by L. iners in a needy individual, the method comprising a step of administering a recombinant endolysin with at least 80% sequence identity to the amino acid sequence as provided in SEQ ID NO: 1 or 37 and with lethal activity against L. iners to said patient. In certain embodiments, the invention relates to a method for reducing the number of L.iners in the vaginoma of a needy individual, the method comprising a step of administering a recombinant endolysin with at least 80% sequence identity to the amino acid sequence as provided in SEQ ID NO: 1 or 37 and with lethal activity against L. iners to said patient.
[0053] The term variant refers to a polypeptide that includes insertions, deletions and / or substitutions, not Petition 870250101940, dated 07 / 11 / 2025, pp. 117 / 190 43 / 97 conservative or, preferably, conservative, with respect to the native amino acid sequence. For example, the polypeptide may comprise an amino acid sequence with at least 80% identity to the native amino acid sequence, preferably at least 85% identity, more preferably at least 90% identity, even more preferably at least 95% identity, even more preferably at least 96% identity, even more preferably at least 97% identity, even more preferably at least 98% identity, even more preferably at least 99% identity, even more preferably at least 99.5% identity, and, most preferably, at least 99.7% identity to said amino acid sequence. The percentage of identity can be determined by well-known methods in the field, using suitable computer programs, for example, MatGAT 2.0 (Myers and Miller, CABIOS (1989). Preferably, the % identity is identified across the entire length of the sequences to be compared. It is important to note that the percentage identity is calculated in relation to polypeptides whose sequence has been optimally aligned. Fragments and variants of an amino acid sequence can be produced using any of the protein engineering methods, directed evolution. Petition 870250101940, dated 07 / 11 / 2025, pages 118 / 190 44 / 97 and / or site-directed mutagenesis well known in the art (e.g., see Molecular Cloning: a Laboratory Manual, 3rd edition, Sambrook & Russell, 2001, Cold Spring Harbor Laboratory Press). Those skilled in the art will understand that a polypeptide according to the invention, or a fragment, variant, or fusion thereof, may comprise or consist of a derivative of a native amino acid sequence, or a fragment or variant thereof. Chemical derivatives of one or more amino acids may be obtained by reaction with a functional side group. Such derivatized molecules include, for example, those molecules in which free amino acid groups have been derivatized to form amine hydrochlorides, p-toluenesulfonyl groups, carboxybenzoxy groups, β-butyloxycarbonyl groups, chloroacetyl groups, or formyl groups. Free carboxyl groups may be derivatized to form salts, methyl and ethyl esters, or other types of esters and hydrazides.Free hydroxyl groups can be derivatized to form O-acyl or O-alkyl derivatives. Also included as chemical derivatives are those peptides containing derivatives of natural amino acids from the twenty standard amino acids. For example: 4-hydroxyproline can be substituted for proline; 5-hydroxylysine can be substituted for lysine; 3-methylhistidine can be substituted for histidine; homoserine can be substituted for serine and ornithine for lysine. Derivatives also include... Petition 870250101940, dated 07 / 11 / 2025, pages 119 / 190 45 / 97 peptides containing one or more additions or deletions, provided that the necessary activity is maintained. Other modifications included are amidation, amino-terminal acylation (e.g., acetylation or amidation with thioglycolic acid), terminal carboxylamidation (e.g., with ammonia or methylamine), and similar terminal modifications. Those skilled in the art will further understand that peptidomimetic compounds may also be useful. Thus, by “polypeptide” we include peptidomimetic compounds that exhibit endolysin activity. The term peptidomimetic refers to a compound that mimics the conformation and desirable characteristics of a specific polypeptide as a therapeutic agent.
[0054] The composition according to the invention may contain one or more endolysin polypeptides. In certain embodiments, the endolysin polypeptides may be present as independent polypeptides or as fusion proteins comprising said endolysin polypeptides or fragments thereof.
[0055] The term “pharmaceutical composition” refers to a preparation that is presented in a form that allows the biological activity of the active ingredient(s) to be unequivocally effective and that does not contain any additional component that is toxic to the patients to whom said composition would be administered. As used in this Petition 870250101940, dated 07 / 11 / 2025, pages 120 / 190 46 / 97 document, “pharmaceutical composition” means a therapeutically effective formulation for use in the methods of the invention. A “therapeutically effective amount,” or “effective quantity,” or “therapeutically effective,” as used herein, refers to the amount that provides a therapeutic effect for a given condition and administration regimen. It is a predetermined amount of active material, calculated to produce a desired therapeutic effect in association with the necessary additive and diluent, i.e., a carrier or administration vehicle. Furthermore, it is intended to mean an amount sufficient to reduce, and more preferably prevent, a clinically significant deficit in the activity, function, and response of the host. Alternatively, a therapeutically effective amount is sufficient to cause an improvement in a clinically significant condition in a host.As is recognized by those skilled in the art, the amount of a compound can vary depending on its specific activity. Suitable dosage amounts may contain a predetermined quantity of the active composition, calculated to produce the desired therapeutic effect in association with the necessary diluent. In the methods and use for manufacturing the compositions of the invention, a therapeutically effective quantity of the active component is provided. A. Petition 870250101940, dated 07 / 11 / 2025, pages 121 / 190 The therapeutically effective amount of 47 / 97 can be determined by a qualified medical or veterinary professional based on patient characteristics such as age, weight, sex, condition, complications, other diseases, etc., as is well known in the art.
[0056] In one embodiment of the invention, the pharmaceutical composition comprises a Gardnerella-specific endolysin, as described herein, and is for use in the treatment of bacterial vaginosis, as described herein. Thus, the pharmaceutical composition may comprise an amount of an endolysin, or fragment, variant, fusion or derivative thereof, sufficient to inhibit, at least in part, the growth of Gardnerella cells in a patient, as described above, who is infected or susceptible to infection by such cells. Preferably, the pharmaceutical composition comprises an amount of endolysin, or fragment, variant, fusion or derivative thereof, sufficient to kill Gardnerella cells in the patient to be treated, as defined above.
[0057] The pharmaceutical composition according to the invention further comprises a pharmaceutically acceptable excipient. The term "pharmaceutically acceptable excipient" refers to an excipient composed of a material that is not biologically or otherwise undesirable. The term "carrier" refers to Petition 870250101940, dated 07 / 11 / 2025, pp. 122 / 190 48 / 97 any components present in a pharmaceutical formulation that are not the active agent and therefore include excipients, diluents, binders, lubricants, disintegrants, fillers, colorants, wetting or emulsifying agents, pH buffering agents, preservatives and the like.
[0058] The inventors have surprisingly discovered that certain excipients, namely polyacrylic acid polymers, can increase the lethal activity of bactericidal polypeptides, in particular endolysins specific to Gardnerella. Thus, in a specific embodiment, the invention relates to the pharmaceutical composition according to the invention, in which the combination of said active agent with said excipient increases the pharmaceutical activity of said active agent.
[0059] In the present invention, an excipient, in particular a polyacrylic acid polymer, “enhances the pharmaceutical activity” of the active agent, i.e., the bactericidal polypeptide specific for Gardnerella, by increasing the lethal activity of said active agent against bacteria of the Gardnerella species. The excipient can increase the pharmaceutical activity of the active agent by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70% or at least 80%. It can be seen in Figure 2 that the PAA excipient increases the Petition 870250101940, dated 07 / 11 / 2025, pp. 123 / 190 49 / 97: Lethal activity of the active agent PM-477 against Gardnerella biofilms is almost 100%, and the lethal activity of the active ingredient H2B10B11 against Gardnerella biofilms is even greater.
[0060] The term “polyacrylic acid polymer, as used herein, describes acrylic acid polymers and includes homopolymers, copolymers, and crosslinked acrylic acid polymers. That is, a polyacrylic acid polymer is a polymer comprising or consisting of the formula (CH2CHCO2H)n.
[0061] In certain embodiments, the polyacrylic acid polymer is a linear polyacrylic acid polymer, in particular a linear polyacrylic acid homopolymer. It was demonstrated in Example 2 that such a polymer significantly increases the lethal activity of endolysins against Gardnerella biofilms. Furthermore, it was demonstrated in Example 3 that a linear polyacrylic acid homopolymer can extend the antimicrobial spectrum of endolysin PM-477 to other bacteria associated with bacterial vaginosis.
[0062] In certain embodiments, the “polyacrylic acid polymer” is a crosslinked polyacrylic acid polymer, such as a carbomer or a carboxyvinyl polymer. A crosslinked polyacrylic acid polymer is a homopolymer or copolymer of acrylic acid crosslinked with at least one other polymer. The term Petition 870250101940, dated 07 / 11 / 2025, pp. 124 / 190 50 / 97 Carbomer refers to a series of acrylic acid polymers commonly used in pharmaceutical compositions. Carbomers are homopolymers or copolymers of high molecular weight acrylic acid crosslinked with polyalkenyl ethers of sugars or polyalcohols. The carbomer contained in the pharmaceutical composition according to the present invention is, preferably, a carbomer that meets the requirements of the American and / or European Pharmacopoeia. Carbomers are marketed under the trade name Carbopol. Thus, in a specific embodiment, the invention relates to the pharmaceutical composition according to the invention, in which said excipient is a carbomer, preferably a Carbopol.
[0063] In certain embodiments, the pharmaceutical composition according to the invention comprises a specific type of carbomer. In certain embodiments, the pharmaceutical composition according to the invention comprises a mixture of two or more different types of carbomers.
[0064] The polyacrylic acid polymer contained in the pharmaceutical composition according to the invention can be defined based on one or more physicochemical properties.
[0065] Preferably, the polyacrylic acid polymer comprised in the pharmaceutical composition according to the invention is defined based on its viscosity. Petition 870250101940, dated 07 / 11 / 2025, pages 125 / 190 51 / 97 That is, the polyacrylic acid polymer included in the pharmaceutical composition according to the invention may exhibit viscosity ranging from 300 - 115,000 mPa-s when in gel form at 0.5% (w / v) (pH 7.3-7.8 at 25°C).
[0066] In certain embodiments, the polyacrylic acid polymer included in the pharmaceutical composition is a type A carbomer, according to the US Pharmacopeia, with a viscosity of 4,000 to 11,000 mPa·s when in the form of a 0.5% (w / v) gel (pH 7.3 to 7.8 at 25°C). In certain embodiments, the type A carbomer is Carbopol 981, Carbopol 971 or Carbopol71G.
[0067] In certain embodiments, the polyacrylic acid polymer comprised in the pharmaceutical composition is a type B carbomer according to the US Pharmacopeia, with a viscosity of 25,000 to 45,000 mPa·s when in the form of a 0.5% (w / v) gel (pH 7.3 to 7.8 at 25°C). In certain embodiments, the type B carbomer is Carbopol 974P, Carbopol 984 or Carbopol 5984, preferably Carbopol 974P.
[0068] In certain embodiments, the polyacrylic acid polymer included in the pharmaceutical composition is a type C carbomer according to the US Pharmacopeia, with a viscosity of 40,000 to 60,000 mPa·s when in the form of a 0.5% (w / v) gel (pH 7.3 to 7.8 at 25°C). In certain embodiments, the type C carbomer is Carbopol 980.
[0069] In certain embodiments, the acid polymer Petition 870250101940, dated 07 / 11 / 2025, pp. 126 / 190 The polyacrylic acid polymer comprised in the pharmaceutical composition according to the invention has a viscosity of 300 - 115,000 mPa·s when in the form of a 0.5% (w / v) gel (pH 7.3-7.8 at 25°C). In certain embodiments, the polyacrylic acid polymer comprised in the pharmaceutical composition according to the invention has a viscosity of 300 - 60,000 mPa·s when in the form of a 0.5% (w / v) gel (pH 7.3-7.8 at 25°C). In certain embodiments, the polyacrylic acid polymer comprised in the pharmaceutical composition according to the invention has a viscosity of 300 - 45,000 mPa·s when in the form of a 0.5% (w / v) gel (pH 7.3-7.8 at 25°C). In certain embodiments, the polyacrylic acid polymer comprised in the pharmaceutical composition according to the invention has a viscosity of 300 - 11,000 mPa·s when in the form of a 0.5% (w / v) gel (pH 7.3-7.8 at 25°C).In certain embodiments, the polyacrylic acid polymer comprised in the pharmaceutical composition according to the invention has a viscosity of 300 - 4,000 mPa·s when in the form of a 0.5% (w / v) gel (pH 7.3-7.8 at 25°C). In certain embodiments, the polyacrylic acid polymer comprised in the pharmaceutical composition according to the invention has a viscosity of 300 - 2,000 mPa·s when in the form of a 0.5% (w / v) gel (pH 7.3-7.8 at 25°C).
[0070] In certain embodiments, the polyacrylic acid polymer included in the pharmaceutical composition of Petition 870250101940, dated 07 / 11 / 2025, pages 127 / 190 53 / 97 according to the invention is a linear polyacrylic acid homopolymer with a viscosity of 300 to 2,000 mPa-s when in the form of a 0.5% (w / v) gel (pH 7.3 to 7.8 at 25°C).
[0071] In certain embodiments, the polyacrylic acid polymer comprised in the pharmaceutical composition according to the invention is a type B carbomer, such as Carbomer 974P, with a viscosity of 25,000 to 45,000 mPa-s when in the form of a 0.5% (w / v) gel (pH 7.3 to 7.8 at 25°C).
[0072] In a specific embodiment, the invention relates to the pharmaceutical composition according to the invention, wherein said excipient is present in a concentration of about 0.1% and 10%.
[0073] That is, the polyacrylic acid polymer may be present in the pharmaceutical composition of the invention at a concentration of about 0.1%, about 0.2%, about 0.25%, about 0.3%, about 0.35%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 1.1%, about 1.2%, about 1.3%, about 1.4%, about 1.5%, about 1.6%, about 1.7%, about 1.8%, about 1.9%, about 2%, about 2.1%, about 2.2%, about 2.3%, about 2.4%, about 2.5%, about 2.6%, about 2.7%, about 2.8%, about 2.9%, about 3%, about 3.1%, about 3.2%, about 3.3%, about 3.4%, about 3.5%, about 3.6%, about 3.7%, about 3.8%, about 3.9%, about 4%, about 4.1%, Petition 870250101940, dated 07 / 11 / 2025, pp. 128 / 190 54 / 97 about 4.2%, about 4.3%, about 4.4%, about 4.5%, about 4.6%, about 4.7%, about 4.8%, about 4.9%, about 5%, about 5.1%, about 5.2%, about 5.3%, about 5.4%, about 5.5%, about of 5.6%, about 5.7%, about 5.8%, about 5.9%, about 6%, about 6.1%, about 6.2%, about 6.3%, about 6.4%, about 6.5%, about 6.6%, about 6.7%, about 6.8%, about 6.9%, about 7%, about 7.1%, around 7.2%, approximately 7.3%, approximately 7.4%, approximately 7.5%, approximately 7.6%, approximately 7.7%, approximately 7.8%, approximately 7.9%, approximately 8%, approximately 8.1%, approximately 8.2%, approximately 8.3%, approximately 8.4%, approximately 8.5%, approximately 8.6%, approximately 8.7%, approximately 8.8%, approximately 8.9%, approximately 9%, approximately 9.1%, approximately 9.2%, approximately 9.3%, approximately 9.4%, approximately 9.5%, approximately 9.6%, approximately 9.7%, approximately 9.8%, approximately 9.9%, or approximately 10%.
[0074] In a particularly preferred embodiment, the invention relates to the pharmaceutical composition according to the invention, wherein said excipient is present in a concentration of about 0.1% to 5%, more preferably about 0.1% to 2.5%, even more preferably about 0.1% to 1%, and much more preferably about 0.2% to 0.5%. In a particularly preferred embodiment, the excipient, in particular the polyacrylic acid polymer, is present in a concentration of about 0.25% or 0.35%. Petition 870250101940, dated 07 / 11 / 2025, pp. 129 / 190 55 / 97
[0075] In certain embodiments, the pharmaceutical composition according to the invention further comprises a salt. It has been surprisingly demonstrated in Figure 7 that increasing the salt concentration in the medium increases the activity of endolysin when formulated together with a polyacrylic acid polymer. The term “salt,” as used herein, generally refers to ionic compounds composed of cations (positively charged ions) and anions (negatively charged ions), such that the product is electrically neutral (without net charge). These component ions may be inorganic or organic ions, monatomic or polyatomic, monovalent or multivalent. Preferably, the salt contained in the pharmaceutical composition according to the invention is a pharmaceutically acceptable salt. In a preferred embodiment, the salt contained in the pharmaceutical composition according to the invention is sodium chloride (NaCl).
[0076] The salt, in particular NaCl, may be present in the composition in any suitable concentration. In certain embodiments, the pharmaceutical composition according to the invention comprises NaCl in a concentration ranging from about 0% to about 12.5%, preferably from about 1% to about 10%, and more preferably from about 2.5% to about 7.5%. In certain embodiments, the pharmaceutical composition according to the invention comprises NaCl in a concentration of about 0.5%, about 1%, about 1.5%, Petition 870250101940, dated 07 / 11 / 2025, pp. 130 / 190 56 / 97 approximately 2%, approximately 2.5%, approximately 3%, approximately 3.5%, approximately 4%, approximately 4.5%, approximately 5%, approximately 5.5%, approximately 6%, approximately 6.5%, approximately 7%, approximately 7.5%, approximately 8%, approximately 8.5%, approximately 9%, approximately 9.5%, approximately 10%, approximately 10.5%, approximately 11%, approximately 11.5%, approximately 12%, or approximately 12.5%. In certain embodiments, the pharmaceutical composition according to the invention comprises NaCl at a concentration of about 0.5%, about 1%, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, about 4.5%, about 5%, about 5.5%, about 6%, about 6.5%, about 7%, about 7.5%, about 8%, about 8.5%, about 9%, about 9.5%, about 10%, about 10.5%, about 11%, about 11.5%, about 12%, or about 12.5%.
[0077] It should be understood that the concentrations given here are to be understood as percentage concentrations by weight / volume (w / v%) when the composition is formulated as a liquid, and as percentage concentrations by weight / weight (w / w%) when the composition is formulated as a solid.
[0078] The pharmaceutical composition provided herein may be used as solids, such as tablets or pre-filled capsules, or liquids, such as solutions, suspensions, emulsions, elixirs or capsules pre-filled therewith, all for oral use, or in the form of a suppository for local use (including intravaginal). However, other means of Petition 870250101940, dated 07 / 11 / 2025, pp. 131 / 190 57 / 97 administration methods are also considered in the context of this invention. Such methods may include, inter alia, parenteral administration(s).
[0079] In addition, pharmaceutical compositions for topical and / or local administration are considered, for example, pharmaceutical compositions in the form of gels, lotions or creams (topical) or by means of a pessary, i.e., a vaginal suppository. Such a pessary / vaginal suppository may be coated with the pharmaceutical composition described herein. The pharmaceutical compositions and their unit pharmaceutical forms may comprise ingredients in conventional proportions, with or without additional active compounds or principles, and such unit pharmaceutical forms may contain any adequate effective amount of the active ingredient, compatible with the intended daily dosage range to be used. The compositions for uses of the invention may also be liquid formulations, including, but not limited to, aqueous or oily suspensions, solutions, emulsions, syrups and elixirs.The compositions may also be formulated as a dry product for reconstitution with water or another suitable vehicle before use. Such liquid preparations may contain additives including, but not limited to, suspending agents, emulsifying agents, non-aqueous vehicles, and preservatives. Suspending agents include, but are not limited to, sorbitol syrup, methylcellulose syrup, etc. Petition 870250101940, dated 07 / 11 / 2025, pp. 132 / 190 58 / 97 glucose / sugar, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel, and hydrogenated edible fats. Emulsifying agents include, but are not limited to, lecithin, sorbitan monooleate, and acacia. Non-aqueous vehicles include, but are not limited to, edible oils, almond oil, fractionated coconut oil, oily esters, propylene glycol, and ethyl alcohol. Preservatives include, but are not limited to, methyl or propyl p-hydroxybenzoate and sorbic acid. Other materials, as well as processing techniques and the like, are presented in Part 5 of Remington's "The Science and Practice of Pharmacy," 22nd Edition, 2012, University of the Sciences in Philadelphia, Lippincott Williams & Wilkins.
[0080] The solid compositions of the invention may be in the form of conventionally formulated tablets or lozenges. The tablets may be coated according to methods well known in the art. The injectable compositions are typically based on sterile injectable saline solution or phosphate-buffered saline solution or other injectable carriers known in the art.
[0081] The pharmaceutical composition of the invention can also be formulated as suppositories, which may contain suppository bases, including, but not limited to, cocoa butter or glycerides. The compositions of this invention also Petition 870250101940, dated 07 / 11 / 2025, pp. 133 / 190 Compositions 59 / 97 can be formulated as transdermal formulations comprising aqueous or non-aqueous vehicles, including, but not limited to, creams, ointments, lotions, pastes, medicated plasters, patches, or membranes. The compositions of the invention can also be formulated for parenteral administration, including, but not limited to, by injection or continuous infusion. Injection formulations may be in the form of suspensions, solutions, or emulsions in oily or aqueous vehicles and may contain formulation agents, including, but not limited to, suspending, stabilizing, and dispersing agents. The composition may also be provided in powder form for reconstitution with a suitable vehicle, including, but not limited to, sterile and pyrogen-free water.
[0082] The pharmaceutical composition of the invention can also be formulated as a depot preparation, which can be administered by implantation or by intramuscular injection. The compositions can be formulated with suitable polymeric or hydrophobic materials (such as an emulsion in an acceptable oil, for example), ion exchange resins or as sparingly soluble derivatives (such as a sparingly soluble salt, for example).
[0083] The pharmaceutical composition of the invention can also be administered in extended-release forms or from extended-release drug dispensing systems. A description of representative materials of Petition 870250101940, dated 07 / 11 / 2025, pp. 134 / 190 60 / 97 extended-release can also be found in Remington's "The Science and Practice of Pharmacy".
[0084] The pharmaceutical composition according to the invention may further comprise one or more pharmaceutically acceptable additional ingredients, such as alum, stabilizers, antimicrobial agents, buffers, colorants, flavorings, adjuvants and the like. It is preferred that the pharmaceutical composition for the uses of the invention does not comprise imidazole.
[0085] The pharmaceutical composition according to the invention is preferably used for the treatment of bacterial vaginosis. Therefore, it is preferred that the pharmaceutical composition according to the invention be formulated for intravaginal dispensing. Consequently, in a specific embodiment, the invention relates to the pharmaceutical composition according to the invention, wherein said composition is suitable for intravaginal dispensing of the active agent. Those skilled in the art are able to formulate a pharmaceutical composition comprising the active agent and the excipient described herein that is suitable for intravaginal dispensing.
[0086] However, the pharmaceutical composition of the invention can also be used for the treatment of bacterial infections, in particular Gardnerella infections, in male individuals. In such embodiments, it is Petition 870250101940, dated 07 / 11 / 2025, pages 135 / 190 61 / 97 prefers that the pharmaceutical composition according to the invention be formulated for administration to the glans, foreskin, or urethral opening. Those skilled in the art are able to formulate a pharmaceutical composition comprising the active agent and excipient described herein that is suitable for dispensing to the glans, foreskin, or urethral opening.
[0087] In a specific embodiment, the invention relates to the pharmaceutical composition according to the invention for use in the treatment of a bacterial infection, preferably bacterial vaginosis.
[0088] That is, the pharmaceutical composition of the invention, comprising the Gardnerella-specific polypeptide and the polyacrylic acid polymer, can be used in the treatment of bacterial infections, in particular bacterial infections caused by bacteria of the genus Gardnerella. Consequently, the pharmaceutical composition of the invention can be used for the treatment of infections caused, without limitation, by one or more species of G. vaginalis sensu stricto, G. leopoldii, G. piotii, and / or G. swidsinskii.
[0089] Gardnerella species, such as G. vaginalis, are the most common cause of bacterial vaginosis. As used in this document, “Bacterial Vaginosis (BV), also referred to in the literature as bacterial vaginosis, nonspecific vaginosis, and nonspecific vaginitis, refers to the most common vaginal infection worldwide. In one embodiment, BV Petition 870250101940, dated 07 / 11 / 2025, pp. 136 / 190 62 / 97 is defined as a pathological state distinguished by the loss of normal vaginal flora, particularly of H2O2-producing Lactobacillus species, and by the simultaneous overgrowth of anaerobic bacteria, frequently including those of the genus Gardnerella. The genus Gardnerella contains at least 13 species, and the most frequent have been renamed G. vaginalis sensu stricto, G. leopoldii, G. piotii, and G. swidsinskii (Vaneechoutte et al., 2019 Int. J. Syst. Evol. Biol. 898661). In a preferred embodiment of the therapeutic use of the invention, the bacterial vaginosis to be treated is a bacterial infection distinguished by the presence of at least one strain of the genus Gardnerella selected from the group consisting of Gardnerella vaginalis sensu stricto, Gardnerella leopoldii, Gardnerella piotii and Gardnerella swidsinskii, and any other species of Gardnerella.Thus, in one embodiment, the pharmaceutical composition according to the invention comprises a Gardnerella-specific endolysin, preferably a recombinant Gardnerella-specific endolysin, as described herein, for use in the treatment of bacterial vaginosis, wherein said bacterial vaginosis is distinguished by the presence of infectious bacteria of the species Gardnerella vaginalis sensu stricto, Gardnerella leopoldii, Gardnerella piotii, Gardnerella swidsinskii, and / or any other species of the genus Gardnerella. It is understood... Petition 870250101940, dated 07 / 11 / 2025, pp. 137 / 190 63 / 97 herein, bacterial vaginosis that is distinguished by the presence of (or is caused by, as used interchangeably herein) certain bacterial species of the genus Gardnerella refers to the overgrowth of these bacteria (also referred to herein as "infectious bacteria") in a patient's vaginal microflora, leading to vaginal dysbiosis and / or loss of Lactobacillus dominance. Methods for determining whether bacterial vaginosis is distinguished by the presence of infectious bacteria of bacterial species of the genus Gardnerella are known to the specialist. As an example, a PCR test that checks for the presence of Gardnerella strains may be used to diagnose bacterial vaginosis.
[0090] It is important to understand that Gardnerella infections can also affect men, potentially causing severe and foul-smelling inflammation and swelling of the inner part of the foreskin and glans. Consequently, the pharmaceutical composition of the present invention can also be used in the treatment of Gardnerella infection in male individuals, particularly when the infection affects the glans penis, the foreskin, or the urethral opening.
[0091] Consequently, in a specific embodiment, the invention relates to the pharmaceutical composition for use according to the invention, which is to be administered locally in a woman's vagina and / or on the glans of the penis, foreskin or Petition 870250101940, dated 07 / 11 / 2025, pp. 138 / 190 64 / 97 entrance to the urethra of a man.
[0092] In a specific embodiment, the invention relates to the pharmaceutical composition according to the invention for use in the treatment of bacterial vaginosis, wherein the polypeptide, in particular endolysin, is to be administered to a patient who has previously not responded to antibiotic treatment and / or who suffers from bacterial vaginosis, in which the infectious bacteria are resistant to antibiotic treatment.
[0093] That is, in certain embodiments, the VB to be treated with the pharmaceutical composition described herein is distinguished by the presence of a Gardnerella strain (i.e., a strain of the genus Gardnerella) resistant to one or more antibiotics. In a preferred embodiment, said one or more antibiotics are selected from the group consisting of nitroimidazoles and clindamycin. In a further preferred embodiment, said Gardnerella strain is resistant to metronidazole, tinidazole, secnidazole, clindamycin, or any combination thereof. In a further preferred embodiment, said Gardnerella strain is resistant to metronidazole and / or clindamycin. In a further preferred embodiment, said Gardnerella strain is resistant to metronidazole. In a further preferred embodiment, said Gardnerella strain is highly resistant to metronidazole. Petition 870250101940, dated 07 / 11 / 2025, pp. 139 / 190 65 / 97
[0094] As used herein, “patient who has previously not responded to antibiotic treatment” refers to a patient with a history of bacterial vaginosis, i.e., who has contracted (or has previously experienced) symptoms of bacterial vaginosis in the past, who was treated for that bacterial vaginosis with antibiotics, and who has experienced a relapse, i.e., for whom the symptoms have reappeared. Such a patient may also be referred to as a patient suffering from recurrent BV.As used in this document, the terms “patient with a history of bacterial vaginosis,” “patient who has previously experienced symptoms of bacterial vaginosis,” and “patient with recurrent BV” may be used interchangeably and include, among others, patients who have experienced one or more episodes of BV, preferably two or more episodes of BV, more preferably two or more episodes of BV in 6 months, even more preferably two or more episodes of BV in the last 6 months, or preferably three or more episodes of BV, more preferably three or more episodes of BV in 12 months, even more preferably three or more episodes of BV in the last 12 months.
[0095] Methods for diagnosing BV in a patient or for confirming episodes of BV are known to those skilled in the art; for example, BV can be diagnosed clinically, using clinical criteria (such as, for example, Amsel's diagnostic criteria) or microscopically. Petition 870250101940, dated 07 / 11 / 2025, pp. 140 / 190 66 / 97 determining the Nugent score from a vaginal Gram stain. Without being bound to any theory, relapses (or recurrences) of BV in patients after antibiotic treatment may be caused by the persistence of a residual infection due to resistance of the infectious bacteria to the antibiotics used. Consequently, in a preferred embodiment of the invention, the patient suffers from bacterial vaginosis in which the infectious bacteria are resistant to antibiotic treatment. Thus, in a preferred aspect of the invention, the Gardnerella-specific pharmaceutical composition described herein is intended for use in the treatment of bacterial vaginosis, wherein the pharmaceutical composition is to be administered to a patient who has previously not responded to antibiotic treatment and who suffers from bacterial vaginosis in which the infectious bacteria are resistant to antibiotic treatment.As defined below, the infectious bacteria of BV to be treated herein are, more preferably, highly resistant to antibiotic treatment. In a preferred embodiment of the therapeutic uses of the invention, the patient to be treated suffers from BV in which the infectious bacteria of said BV are resistant, preferably highly resistant, to treatment with Metronidazole, Tinidazole, Secnidazole, Clindamycin, or any combination thereof. In a... Petition 870250101940, dated 07 / 11 / 2025, pages 141 / 190 67 / 97 In a further preferred embodiment of the therapeutic uses of the invention, the patient to be treated suffers from BV in which the infectious bacteria of said BV are resistant, preferably highly resistant, to treatment with Metronidazole and / or Clindamycin. In a further preferred embodiment of the therapeutic uses of the invention, the patient to be treated suffers from BV in which the infectious bacteria of said BV are resistant, preferably highly resistant, to treatment with Metronidazole.
[0096] In the context of the present invention, “resistance of bacterial strains (preferably Gardnerella strains) to antibiotics” refers to the ability of strains to resist the activity of the antibiotic to which they were previously susceptible and allow them to survive antibiotic treatment. Antibiotic resistance can occur naturally (“intrinsic resistance”) or can be induced by the misuse of antibiotics in humans and animals (“acquired resistance”). Methods for determining the resistance or susceptibility of bacterial strains to antibiotics are known to those skilled in the art. As an example, EUCAST breakpoints for Gram-positive anaerobes (v11, 2021) can be used. An alternative definition is presented in Petrina et al. (2017, Anaerobe 47, 115-119), where slightly higher resistance breakpoints are used, since the formulations Petition 870250101940, dated 07 / 11 / 2025, pp. 142 / 190 Topical applications of some nitroimidazoles and clindamycin can establish concentrations in the mg / ml range in vaginal fluid, much higher than those achieved with orally administered antibiotics. According to this alternative and more rigorous definition (also used in the attached examples), Resistance (R) can be defined as an MIC value greater than or equal to 32 μg / ml for Metronidazole and as an MIC value greater than 8 μg / ml for Clindamycin, while Sensitivity (S) can be defined as an MIC value less than or equal to 8 μg / ml for Metronidazole and less than or equal to 2 μg / ml for Clindamycin. The terms “Minimum Inhibitory Concentration” and “MIC” are used here interchangeably and refer to the lowest concentration of a chemical substance, usually a drug, that prevents visible bacterial growth. The MIC can be defined as the minimum antibiotic concentration at which no growth was detectable after 48 hours by OD measurement.Consequently, in a preferred embodiment of the therapeutic uses of the invention, the patient to be treated suffers from BV in which the infectious bacteria are resistant to antibiotic treatment, as defined by the EUCAST breakpoints. Other generally accepted resistance criteria may be used instead of and / or in addition to the EUCAST definition or the alternative definition mentioned above (Petrina et al., 2017, Anaerobe 47, 115-119). Petition 870250101940, dated 07 / 11 / 2025, pages 143 / 190 69 / 97 define the resistance of infectious bacteria to antibiotic treatment in the context of the present invention.
[0097] As those skilled in the art will know, “resistance” and “susceptibility” can also be defined in terms of MBC and / or SBEC values. The terms “Minimum Bactericidal Concentration” or “MBC” refer to the lowest concentration of an antibacterial agent required to kill a specific bacterium. Typically, MBC90 or MBC99.5 is measured, that is, the concentration of antibiotic that kills 90% or 99.5%, respectively, of the cells in a defined time. MBC can be defined as the minimum concentration that completely eradicates a suspension of, for example, 2.5 x 10⁷ CFU / ml. While the MIC is the lowest concentration of an antibacterial agent required to inhibit visible growth, the MBC is the minimum concentration of an antibacterial agent that results in the bacterial death of all cells in suspension up to a defined detection limit, resulting in the death of at least 90% (MBC90) or at least 99.5% (MBC99.5) of the bacteria.The terms "Minimum Biofilm Eradication Concentrations" or "MEBC" refer to the lowest concentration of an antibacterial agent needed to reduce a population of bacteria growing as a biofilm below the detection limit.
[0098] Without being bound to any theory, the Petition 870250101940, dated 07 / 11 / 2025, pp. 144 / 190 70 / 97 Resistance of infectious bacteria to antibiotics may be involved in (or partially or substantially responsible for) relapses (or recurrences) of BV in patients suffering from recurrent BV. Therefore, a patient suffering from bacterial vaginosis, in which the infectious bacteria are resistant to antibiotic treatment, is likely to fail antibiotic treatment. Thus, in a preferred embodiment of the invention, the patient to be treated, who suffers from bacterial vaginosis in which the infectious bacteria are resistant to antibiotic treatment, is a patient prone to antibiotic treatment failure.As used in this document, a patient “prone to antibiotic treatment failure” refers to a patient who has a high risk of antibiotic treatment failure, i.e., for whom the likelihood of relapse (e.g., within 12 months) is very high if said patient were treated with antibiotics. Methods for determining whether a patient is prone to antibiotic treatment failure are known to those skilled in the art. As an example, a clinical sample can be collected and the resistance of vaginal microflora strains evaluated. Similarly, a patient suffering from bacterial vaginosis, in which the infectious bacteria are resistant to antibiotic treatment, is likely already (i.e., Petition 870250101940, dated 07 / 11 / 2025, pages 145 / 190 71 / 97 previously) failed antibiotic treatment (as defined above). Consequently, in another preferred embodiment of the invention, the patient to be treated, who suffers from bacterial vaginosis in which the infectious bacteria are resistant to antibiotic treatment, is a patient who previously failed antibiotic treatment.
[0099] According to the above definition of resistance, “High Resistance” (HR) can be defined as an MIC value greater than or equal to 256 μg / ml for Metronidazole and an MIC value greater than 64 μg / ml for Clindamycin, i.e., 8 times greater than the resistance cut-off points of the alternative definition, which in turn are already greater than the standard resistance cut-off points of the EUCAST definition. Consequently, in one embodiment of the therapeutic uses of the invention, the patient to be treated suffers from BV in which the infectious bacteria of said BV are resistant, preferably highly resistant, to antibiotic treatment, preferably as defined by the EUCAST cut-off points.In a preferred embodiment of the therapeutic uses of the invention, the patient to be treated suffers from BV in which the infectious bacteria of said BV are resistant, preferably highly resistant, to treatment with Metronidazole, Tinidazole, Secnidazole, Clindamycin, or any combination thereof. In a... Petition 870250101940, dated 07 / 11 / 2025, pages 146 / 190 72 / 97 In a further preferred embodiment of the therapeutic uses of the invention, the patient to be treated suffers from BV in which the infectious bacteria of said BV are resistant, preferably highly resistant, to treatment with Metronidazole and / or Clindamycin. In a further preferred embodiment of the therapeutic uses of the invention, the patient to be treated suffers from BV in which the infectious bacteria of said BV are resistant, preferably highly resistant, to treatment with Metronidazole.
[00100] In certain embodiments, the pharmaceutical composition according to the invention is used in the treatment of bacterial vaginosis, wherein the said patient has not previously responded to antibiotic treatment and / or wherein the infectious bacteria of said bacterial vaginosis are resistant to antibiotic treatment.
[00101] As used in this document, the terms “antibiotic treatment” and “antibiotic therapy” are used interchangeably and preferably refer to treatment with antibiotics recommended or approved for the treatment of BV. Antibiotics currently recommended or approved for the treatment of BV include nitroimidazoles, including, but not limited to, metronidazole, tinidazole, secnidazole, and clindamycin. Thus, in one embodiment, the aforementioned “antibiotic treatment” or “antibiotic therapy” is a Petition 870250101940, dated 07 / 11 / 2025, pages 147 / 190 73 / 97 treatment with nitroimidazole and / or clindamycin. In a preferred embodiment, the antibiotic treatment described herein is treatment with metronidazole, tinidazole, secnidazole, clindamycin, or any combination thereof. In a more preferred embodiment, the antibiotic treatment described herein is treatment with metronidazole and / or clindamycin. In a still more preferred embodiment, the antibiotic treatment described herein is treatment with metronidazole.
[00102] As used herein, “treatment,” “treating,” and the like generally mean the attainment of a desired pharmacological and physiological effect. The effect may be prophylactic in terms of prevention or partial prevention of a disease, symptom, or condition thereof, and / or may be therapeutic in terms of partial or complete cure of a disease, condition, symptom, or adverse effect attributed to the disease. The term “treatment,” as used herein, encompasses any treatment of bacterial vaginosis in a mammal, particularly in a human being, and includes: (a) preventing the occurrence of bacterial vaginosis in a patient who may be predisposed to bacterial vaginosis but not yet diagnosed; (b) inhibiting bacterial vaginosis, i.e., halting its development; or alleviating bacterial infection, i.e., causing regression of the bacterial infection and / or its symptoms or conditions, such as improvement Petition 870250101940, dated 07 / 11 / 2025, pages 148 / 190 4 / 97 or remediation of the damage. In particular, the treatment of bacterial vaginosis involves preventing, reducing, or even eradicating the infection, for example, by eliminating the infectious bacteria and thus controlling, reducing, or inhibiting bacterial proliferation, as well as reducing the number of viable bacterial cells. Here, it is preferred that the disease, i.e., BV, be treated therapeutically in terms of partial or complete cure of the disease or symptoms.
[00103] Those skilled in the art will understand that the active agent to be used according to the invention is generally administered in a mixture with a suitable pharmaceutical excipient, diluent or carrier, selected in relation to the intended route of administration and standard pharmaceutical practice (e.g., see Remington: The Science and Practice of Pharmacy, 19th edition, 1995, Ed. Alfonso Gennaro, Mack Publishing Company, Pennsylvania, USA). For example, the active agent may be administered locally, i.e., locally in the vagina of a woman and / or, in a man, on the glans, foreskin or urethral opening.
[00104] Here, the term “(administration) on the glans” also includes “(administration) on the glans”. In line with this, the term “(administration) on the glans, foreskin or urethral entrance of a male individual” also includes “(administration) on the glans, foreskin and urethral entrance of a male individual”. In another Petition 870250101940, dated 07 / 11 / 2025, pages 149 / 190 In the 75 / 97 embodiment, the active agent may be co-administered with a compound or composition that adjusts the pH of the vagina. In some embodiments, the compound or composition adjusts the pH of the vagina to pH 4.0 to 6.0, preferably to pH 5.0.
[00105] The terms “patient” and “individuals” are used interchangeably herein and refer to mammals. For example, mammals contemplated by the present invention include humans, primates, domestic animals such as cattle, sheep, pigs, horses, laboratory rodents and the like. It is preferred that the patient be a human being. It is even more preferable that the patient be a woman (also referred to herein as a “female individual”).
[00106] It should be noted that pharmaceutical compositions for uses as described herein may be administered to an individual in combination with one or more additional therapeutic agents. For example, the endolysins and pharmaceutical compositions described herein may be administered to an individual in combination with: (a) one or more conventional antibiotic treatments. Such antibiotics may include Clindamycin, Metronidazole or any other suitable antibiotics known to a person skilled in the art; (b) one or more additional endolysins, or nucleic acid molecules, vectors, host cells or bacteriophages capable of expressing them; Petition 870250101940, dated 07 / 11 / 2025, pages 150 / 190 76 / 97 (c) a compound or composition that adjusts the pH of the vagina, preferably to pH 4.0 to 6.0, more preferably to pH around 5.0. Such pH-adjusting compounds may include phosphate, lactic acid (e.g., the natural acidifying substance that Lactobacilli secrete to establish an acidic environment) or other organic acids, e.g., carboxy-substituted polymers; (d) a therapy to neutralize toxins released by bacterial lysis of G. vaginalis cells within the vagina. Suitable neutralizing therapies may include antibodies (see Babcock et al., 2006, Infect. Immun. 74:6339-6347) and toxin-absorbing agents such as tolevamer (see Barker et al., 2006, Aliment. Pharmacol. Ther. 24:1525-1534); (e) a probiotic.
[00107] In one embodiment of the uses of the invention, a host cell or pharmacological composition comprising a host cell is used to deliver endolysin (preferably a host cell).
[00108] In a specific embodiment, the invention relates to the use of the pharmaceutical composition according to the invention for the manufacture of a medicament for the treatment or prevention of a bacterial infection, preferably bacterial vaginosis.
[00109] In a specific embodiment, the invention is Petition 870250101940, dated 07 / 11 / 2025, pages 151 / 190 77 / 97 refers to a method for treating or preventing a bacterial infection, preferably bacterial vaginosis, in an individual in need, comprising administering to said individual a therapeutically effective amount of the pharmaceutical composition according to the invention.
[00110] The present invention also provides a method for treating a bacterial infection, in particular bacterial vaginosis, as described above, wherein the method comprises administering to said patient a therapeutically effective amount of a pharmaceutical composition comprising a Gardnerella-specific polypeptide, preferably a Gardnerella-specific endolysin, and a polyacrylic acid polymer.
[00111] The modalities and definitions described above for the therapeutic uses according to the invention apply in the context of the VB mutatis mutandis treatment method.
[00112] One aspect of the invention relates to a composition comprising a polyacrylic acid polymer for use in the treatment and / or prevention of bacterial infections, wherein the polyacrylic acid polymer reduces biofilms.
[00113] In another aspect, the invention relates to a non-therapeutic use of a polyacrylic acid polymer in reducing bacterial biofilms. Petition 870250101940, dated 07 / 11 / 2025, pages 152 / 190 78 / 97
[00114] That is, the inventors surprisingly found that polyacrylic acid polymers can reduce Gardnerella biofilms, even in the absence of a specific Gardnerella polypeptide; see Figures 2A and B. In contrast, polyacrylic acid polymers do not exhibit lethal activity against planktonic Gardnerella; see FIG. 5. Thus, it has been demonstrated that polyacrylic acid polymers act specifically against bacterial biofilms. Based on these findings, polyacrylic acid polymers can be used as components of pharmaceutical compositions for the treatment and / or prevention of bacterial infections, particularly when bacterial infections involve biofilm formation.
[00115] A polyacrylic acid polymer is defined as being able to reduce or dissolve biofilms if contact of the polyacrylic acid polymer with a biofilm reduces the number of viable bacteria (CFU / mL) in the biofilm by a factor of at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10.
[00116] For this purpose, biofilms (e.g., of G. vaginalis ATCC 14018) can be generated in sBHIG (in g / L: Brain Heart Infusion: 37, gelatin: 20, yeast extract: 5, starch: 1, glucose: 2.5; water: up to 1000 mL) pH 7 for 48 hours in pre-prepared tissue culture plates. Petition 870250101940, dated 07 / 11 / 2025, pages 153 / 190 79 / 97 coated. The resulting biofilms can then be treated in sBHIG pH 4.5 for 24 hours with PAA. Alternatively, biofilms can be generated in sNYC (in g / L: HEPES: 2.4, proteose peptone: 15, yeast extract: 3.8, NaCl: 5, glucose: 10; water: up to 1000 mL) pH 7 for 48 h, and can then be treated with PAA in sNYC pH 6 for 24 h. For biofilm treatment with PAA, a PAA master stock (27% (w / v)) can be used to prepare a 0.35% PAA (v / v) working stock. After incubation, the biofilm can be washed and dislodged by vigorous pipetting. A serial dilution can be performed in PBS (1xPBS - DPBS, calcium-free, magnesium-free, Thermo Scientific, cat. no. 14190169) and applied to Chocolate Agar plates (BD, cat. no. 254060) for counting the number of viable cells (CFU / ml).
[00117] In certain forms, the bacterial biofilm is a mucous biofilm. In certain forms, the (mucous) biofilm is formed by bacteria of the genus Gardnerella.
[00118] In certain forms, the bacterial infection is bacterial vaginosis, as defined above.
[00119] Preferably, the pharmaceutical composition further comprises a polypeptide with lethal activity against Gardnerella, as described herein. That is, it has been demonstrated in Figure 2 that polyacrylic acid acts synergistically with endolysin PM-477 against biofilms. Petition 870250101940, dated 07 / 11 / 2025, pages 154 / 190 Gardnerella 80 / 97
[00120] The polyacrylic acid polymer comprised in the pharmaceutical composition according to the invention may be a cross-linked polyacrylic acid polymer or a carbomer. The definitions of polyacrylic acid polymer described herein apply mutatis mutandis.
[00121] The term “approximately”, as used herein, refers to a numerical value, including, for example, whole numbers, fractions and percentages, whether or not explicitly stated. The term “approximately” generally refers to a range of numerical values (e.g., + / - 13% of the stated value) that a person skilled in the art would consider equivalent to the stated value (e.g., having the same function or result). In some cases, the term “approximately” may include numerical values rounded to the nearest significant digit.
[00122] The present invention is described in more detail by reference to the following figures and non-limiting examples. BRIEF DESCRIPTION OF THE DRAWINGS
[00123] Fig. 1: A. Kinetic study of PM-477 against G. vaginalis Gv9 (ATCC 14018T) shows a strong time- and dose-dependent lytic effect. Gardnerella cell suspensions were treated with recombinantly expressed PM-477 for 1 h, 5 h and 24 h, and at 2.5, 10 and 40 μg / ml, and the Petition 870250101940, dated 07 / 11 / 2025, pp. 155 / 190 81 / 97 colony-forming units (CFU) per ml were determined on a logarithmic scale and compared to a buffer-treated control. B, Suspensions of other vaginal bacterial vaginosis pathogens (in gray), as well as probiotic lactobacilli (in white boxes), were treated with PM-477 for 5 hours at 10 and 100 μg / ml, and colony-forming units (CFU) per ml were determined on a logarithmic scale and compared to a buffer-treated control. LOD indicates the limit of detection. Statistical significance (one-way ANOVA, comparison of control with 10 and 10 μg / mL PM-477 treatment for each strain) is indicated; ***, P< 0.001, **, P< 0.01, *, P< 0.05.
[00124] Fig. 2: A, Gardnerella biofilms (using the G. vaginalis ATCC 14018 type strain) were treated with 8 μg / ml of PM-477 (and therefore below the concentration typically used to eradicate Gardnerella biofilms), 0.35% (w / v) PAA and a combination thereof, for 24 hours at pH 4.5 in sBHIG medium. B, Gardnerella biofilms (G. vaginalis ATCC 14018) were treated with 32 μg / ml of H2B10B11, 0.25% (w / v) PAA and a combination thereof, for 24 hours at pH 6 in sNYC medium.
[00125] The cells were dislodged by pipetting and quantitative plating was used to determine the remaining viable cells (CFU / ml). The bactericidal effect is visualized by logio reductions in CFU / ml compared to the Petition 870250101940, dated 07 / 11 / 2025, pages 156 / 190 82 / 97 buffer-treated control. The gray column indicates the theoretical additional effect of the mean logarithmic reduction of PM477 / H2B10B11 and PAA. Mean values with standard deviation are shown.
[00126] Fig. 3: Lytic activity of two PM-477 formulations on six pathogens associated with bacterial vaginosis and a commensal Lactobacillus species. The sensitivity of the strains was tested by treating fresh liquid culture suspensions of the strains for 5 hours with a control without EL, PM-477 formulated with PAA at pH 4.5 (panel A) or PM477 formulated with PAA at pH 5.0 (panel B). Viability after the indicated treatment was determined by quantitative spotting (panels A and B) and the reduction in viability for both formulations (panel C) was calculated by subtracting the log10 CFU / mL in replicates of the formulation treatments from the median of the respective unmodified control. Triplicates, range and median are shown. LOD: limit of detection. Points below the LOD indicate that the limit of detection has been reached.
[00127] Fig. 4: Influence of PAA concentration on the viability of Gv9 planktonic cells. Sensitivity to PAA was tested by treating fresh liquid culture suspensions of Gv9 with sNYCB pH 5, with varying concentrations of PAA, for 90 minutes at 37°C. Viability after treatment was determined by quantitative spotting. [Image showing...] Petition 870250101940, dated 07 / 11 / 2025, pages 157 / 190 83 / 97 triplicates and interval with a horizontal line in the median. PAA: poly(acrylic acid). LOD: limit of detection.
[00128] Fig. 5: Influence of PAA on the viability of five pathogens associated with bacterial vaginosis and one commensal. The sensitivity of the strains to PAA was tested by treating fresh liquid culture suspensions with NYCB pH 5 medium, with PAA concentrations ranging from 0.01% to 1%, for 90 minutes, and comparing them with untreated controls. Viability after treatment was determined by quantitative spotting. Data are presented in triplicate, with a line in the median. PAA: polyacrylic acid. LOD: limit of detection. Points below the LOD indicate that the limit of detection has been reached.
[00129] Fig. 6: Lytic activity of H2B10B11 formulated with Carbopol 974P against pathogens associated with bacterial vaginosis and a commensal. The sensitivity of the strains was tested by treating fresh liquid culture suspensions of the strains for 20.5 h with a control without EL or with a low concentration of H2B10B11 (2 μg / mL) formulated with 0.25% (w / v) CP 974P in medium adjusted to pH 5. Viability after the indicated treatment was determined by quantitative spotting. Triplicates and median are shown. LOD: limit of detection. Spots below the LOD indicate that the limit of detection has been reached.
[00130] Fig.7 : The activity of H2B10B11 formulated with Petition 870250101940, dated 07 / 11 / 2025, pages 158 / 190 84 / 97 Carbopol is adjustable by modulating the salt content. A 90-minute lytic potency assay in Gardnerella vaginalis was performed with 10 μg / mL of H2B10B11 and / or 0.1% (w / v) Carbopol in medium adjusted to pH 5.5 with normal (86 mM, circle) and high (345 mM, diamond) salt concentrations. The potency of H2B10B11 was assessed by quantitative spotting. Triplicates with median and range are shown.
[00131] Fig. 8: Reduction of L. iners in swab samples from women positive for bacterial vaginosis after 19 h treatment. Thirty vaginal swab samples were treated overnight with 50 μg / mL of H2B10B11 (black) or with 50 μg / mL of H2B10B11 formulated with 0.1% (w / v) CP 974P and 1% NaCl (gray). Viable L. iners load was determined by viability qPCR using a pair of L. iners-specific primers. DNA copies / μL in treated samples subtracted from the load in the respective untreated baseline samples are plotted over the load in the baseline samples. Linear regression between samples was performed; the slope is shown in the graph. EXAMPLES Example 1 - Endolysin PM-477 is a highly active antibacterial enzyme that targets the genus Gardnerella and, to a lesser extent, Lactobacillus iners.
[00132] Bacterial vaginosis (BV) is distinguished by Petition 870250101940, dated 07 / 11 / 2025, pp. 159 / 190 85 / 97 an imbalance of the vaginal microbiome and a characteristic biofilm formed on the vaginal epithelium, which is initiated and dominated by the bacterium Gardnerella. The inventors previously described synthetic endolysins, derived from the 1,4-beta-N-acetylmamidase enzyme encoded in Gardnerella prophages (WO 2020 / 225335). These endolysins efficiently eliminate the bacterium Gardnerella and, to a lesser extent, also L. iners, another opportunistic pathogen of BV. It is important to note that probiotic Lactobacilli, such as L. crispatus and L. gasseri, are not harmed by treatment with PM-477. The inventors tested the lethal activity of a representative endolysin (PM-477 (H2B10)) on Gardnerella vaginalis.
[00133] Gardnerella bacteria in suspension (OD = 0.1) were treated with endolysin PM-477 (stock solution 700 μg / ml PM-477 in 50 mM MES pH 5.5, 200 mM NaCl, 8 mM MgSO4) or with a control buffer and incubated anaerobically for 1, 5, and 24 hours. After the incubation period, the suspension was serially diluted, inoculated onto chocolate agar plates, and CFU / ml was counted. Efficacy was clearly time- and dose-dependent, and even low concentrations of 10 and 40 μg / ml after 5 hours of incubation reduced the number of cells to the limit of detection (LOD). No regrowth was observed after 24 h. Interestingly, no additional deaths were recorded between 5 h and 24 h when treated with Petition 870250101940, dated 07 / 11 / 2025, pages 160 / 190 86 / 97 very low concentration of 2.5 μg / ml, indicating that an equilibrium may have formed. The inventors also tested the activity of PM-477 on other opportunistic vaginal pathogens, as well as on probiotic vaginal lactobacilli. PM-477 proved to be specific for the bacterium Gardnerella without affecting beneficial lactobacilli or other opportunistic pathogens of BV. The only exception was L. iners, where high concentrations of 100 μg / ml after 5 hours reduced the number of bacteria by 2.5 log10 units. L. iners clearly differs from other lactobacilli in terms of cell wall constitution and metabolism and is considered a pathogen in BV.
[00134] In summary, a strong bactericidal effect against Gardnerella was demonstrated for recombinant endolysin PM-477 (H2B10) without harming L. crispatus, L. gasseri, and L. jensenii, which are the most prevalent species in a healthy vaginal microbiome (see FIG. 1). Example 2 - PAA as an excipient intensifies the lethal effect of endolysins on Gardnerella bacteria growing as a biofilm.
[00135] The inventors tested PAA (Sigma Aldrich, catalog number 323667-100G) as a vehicle for Gardnerella-specific endolysins for intravaginal application. The viscosity and mucoadhesive properties of PAA ensure a slow release of Petition 870250101940, dated 07 / 11 / 2025, pp. 161 / 190 The active pharmaceutical ingredient 87 / 97 (endolysin) is found in the vaginal mucus layer, and its acidifying effect helps restore a healthy vaginal microbiome. Unexpectedly, the presence of PAA also intensified the potency of the endolysins, and Gardnerella bacteria were eliminated more efficiently. The inventors tested the Gardnerella-specific endolysins PM-477 and H2B10B11 formulated with PAA on monospecies Gardnerella biofilms in vitro. Biofilms (G. vaginalis ATCC 14018) were generated in sBHIG (in g / L: Brain Heart Infusion: 37, gelatin: 20, yeast extract: 5, starch: 1, glucose: 2.5; water: up to 1000 mL) pH 7 for 48 hours in pre-coated tissue culture plates, subsequently treated in sBHIG pH 4.5 for 24 hours with low concentrations of endolysin PM-477 together with PAA, as well as PM-477 and PAA alone.Alternatively, biofilms were generated in sNYC (in g / L: HEPES: 2.4, proteose peptone: 15, yeast extract: 3.8, NaCl: 5, glucose: 10; water: up to 1000 mL) pH 7 for 48 h, then treated with H2B10B11 or PAA, or a combination of both, in sNYC pH 6 for 24 h.
[00136] For biofilm treatment with PAA and PM477, a PAA master stock (27% (w / v)) was used to prepare a 0.35% PAA (v / v) working stock by dilution with sBHIG pH 5, containing 8 μg / ml of PM-477 (the 700 μg / ml PM-477 master stock was used for the Petition 870250101940, dated 07 / 11 / 2025, pp. 162 / 190 88 / 97 dilutions). Furthermore, the final mixture of PM-477 with the PAA excipient used for biofilm treatment had a pH of 4.5 due to the buffering effect of 0.35% PAA. For biofilm treatment with PAA and H2B10B11, a master stock of PAA (14.5% (w / v), adjusted to pH 6) was used to prepare a treatment solution containing 0.25% PAA and 32 μg / mL H2B10B11 in sNYC pH 6. After incubation, the biofilm was washed and dislodged by vigorous pipetting. A serial dilution was performed in PBS (1xPBS - DPBS, calcium-free, magnesium-free, Thermo Scientific, cat. no. 14190169) and inoculated onto Chocolate Agar plates (BD, cat. no. 254060) for viable cell count (CFU / mL). For the tested strains, the PM-477 concentration for Gardnerella biofilm eradication ranged from 2 to 32 μg / mL.The concentration chosen in this study was 8 μg / ml and, therefore, is at the lower end of the minimum biofilm eradication concentration (MBEC) range for Gardnerella strains, allowing us to observe a potential synergistic effect of the PAA and PM-477 excipients. It is noted that the MBEC is influenced by the medium and pH used in the experiment. As the biofilm experiment with H2B10B11 was performed at pH 6, 32 μg / mL of H2B10B11 was not sufficient to eradicate the biofilm in the absence of PAA.
[00137] PM-477 (8 μg / ml) alone reduced CFU / ml by 1.6 logi units, PAA (0.35% w / v) alone Petition 870250101940, dated 07 / 11 / 2025, pages 163 / 190 89 / 97 in 0.6 logic units, while the combination of PM-477 and PAA resulted in a clearly synergistic effect with mortality rates of 3 logic units. The difference in relation to the potential additive effect (0.6 logic units of PAA and 1.6 logic units of PM-477 = reduction of 2.2 logic units) was 0.8 log units (3 logic units in total), which translates to a 6-fold increase in activity on a linear scale (FIG. 2A).
[00138] No relevant effect was observed with H2B10B11 (32 μg / mL) alone in pH 6 medium. PAA (0.25% w / v) alone reduced CFU / mL by 0.9 logic units, while the combination of H2B10B11 and PAA resulted in a clear synergistic effect, with a reduction of 3.1 logic units (FIG. 2B). Example 3 - PAA as an excipient intensifies the lethal effect of endolysins on Gardnerella bacteria and other planktonic bacterial vaginosis pathogens.
[00139] Next, the potency of two different PM-477 formulations with 0.25% PAA (w / v; Sigma Aldrich, catalog number 323667-100G) as excipient was tested against six pathogens associated with bacterial vaginosis and one commensal Lactobacillus species in an elimination time assay (FIG. 3). Both formulations included 2 μg / mL of PM-477 and 0.25% PAA and were adjusted to pH 4.5 (FIG. 3A) or pH 5 (FIG. 3B) to simulate different types and Petition 870250101940, dated 07 / 11 / 2025, pp. 164 / 190 90 / 97 compositions of PAA. Briefly, 4 g of PAA were added to 10 mL of dH2O and heated to 50°C while mixing on a heated stirrer plate. The pH of the PAA solutions was adjusted to 4.5 or pH 5 using 5 M NaOH. Then, the volumes were adjusted to 27.5 mL (corresponding to 14.5% PAA) and sterile filtered using a 0.22 μm syringe filter. These stocks were diluted to a final concentration of 0.25% PAA in glucose-supplemented New York City Broth medium (sNYCB) adjusted to the respective pH. The supplemented NYCB consists of 10 mM HEPES (Sigma Aldrich), 15 g / L Proteose Peptone (Sigma Aldrich), 3.8 g / L yeast extract (Thermo Fisher Scientific), 86 mM sodium chloride (Carl Roth), and 10 g / L α-D-glucose (Sigma Aldrich).
[00140] The bacteria were cultured anaerobically on Chocolate Agar plates for 48 ha at 37°C, then scraped from the plates, and suspensions of 10⁸ CFU / ml were prepared for the experiment. For the elimination time experiments, the bacterial suspensions were mixed with the respective treatment stock solutions and incubated anaerobically for 5 ha at 37°C. Subsequently, the surviving bacteria were quantified by applying 2 μL of a series of 10-fold dilutions (minimum dilution of 10⁻⁵) to Chocolate Agar plates after anaerobic incubation at 37°C for 48 h. Petition 870250101940, dated 07 / 11 / 2025, pages 165 / 190 91 / 97
[00141] Both formulations were highly effective in reducing the bacterial load of all six pathogens, but had no negative effect on the commensal L. crispatus (FIG. 3). The formulation adjusted to a slightly more acidic pH (4.5) reduced viable Gv9 (G. vaginalis ATCC 14018), L. iners, M. mulieris, by > 3 logic and A. vaginae and P. bivia by > 2 logic compared to controls (FIG. 3C). When formulated to a less acidic pH (5.0), 2 μg / mL of PM-477 reduced Gv24 (G. swidsinskii GS 9838-1), L. iners and P. bivia by > 3 logic and Gv9, M. mulieris and A. vaginae by > 2 logic compared to controls, without any negative effect on the commensal L. crispatus (FIG. 3C).
[00142] In summary, the formulation with PAA surprisingly broadens the spectrum of activity of PM-477 to multiple pathogens associated with bacterial vaginosis, in addition to Gardnerella. Example 4 - PAA alone has no lethal effect on Gardnerella and has a weak lethal effect on some other BV pathogens, but only at higher concentrations.
[00143] Next, the effect of PAA (Sigma Aldrich, catalog number 323667-100G) alone on Gardnerella and other pathogens associated with BV was evaluated. As described in the previous Examples, the bacterial suspensions were adjusted to 10⁸ CFU / ml, mixed with Petition 870250101940, dated 07 / 11 / 2025, pages 166 / 190 92 / 97 stock treatment solutions were incubated anaerobically for 90 minutes at 37°C, after which the surviving bacteria were quantified by spotting a series of 10-fold dilutions of the reactions. The spot plates were incubated for 2–3 days before determining CFU / mL. As shown in Figure 4, PAA concentrations as low as 1% did not reduce Gardnerella viability after 90 minutes of incubation.
[00144] The sensitivity of five other pathogens associated with bacterial vaginosis and a commensal Lactobacillus species to PAA was also tested using the same assay. The four pathogens associated with bacterial vaginosis tested were L. iners, P. bivia, A. vaginae, and M. mulieris, while L. crispatus was used as a commensal (Figure 5). The inventors tested PAA concentrations ranging from 0.01% to 1%, adjusted to pH 5, in all five organisms using 90-minute potency assays. PAA concentrations up to 1% had minimal influence (reduction < 0.6 logio) on the viability of M. mulieris and L. crispatus. The viability of P. bivia and A. vaginae decreased by 1.8 and 1.7 logio only in response to high PAA concentrations (> 0.5%), with lower concentrations showing no effect (FIG. 5). The viability of L. iners decreased by ~1.1 log10 in response to the lowest tested concentrations of PAA (0.01%) and did not decrease further with higher concentrations of PAA (FIG. 5). Petition 870250101940, dated 07 / 11 / 2025, pages 167 / 190 93 / 97 Example 5 - Carbopol 974P as an excipient intensifies the lethal effect of endolysins on planktonic pathogens associated with bacterial vaginosis, but not on commensal Lactobacillus species.
[00145] The potency of H2B10B11 formulated with 0.25% (w / v) NF Carbopol 974P Polymer (CP 974; The Lubrizol Corporation) was tested against five pathogens associated with bacterial vaginosis and a commensal species of Lactobacillus in a planktonic environment for 5 h in sNYC medium at pH 5 (FIG. 6). The formulation contained 2 μg / mL of H2B10B11 and 0.25% of CP 974P, with a final pH of 5. To produce the formulated treatment solution, 50 mg of CP 974P were added to 15 mL of sNYC pH 5. After mixing, the pH was readjusted to pH 5 using 5 M NaOH, and the volume adjusted to 20 mL with sNYC pH 5. H2B10B11 was added at a final concentration of 2 μg / mL from a stock of 1.343 mg / mL in MES buffer pH 5.5.
[00146] Gardnerella was cultured on a chocolate agar plate, the other bacterial strains on Schaedler agar plates with vitamin K1 and 5% sheep blood (BD, catalog number 254042) anaerobically for 48 ha at 37°C, then scraped from the plates, and suspensions of 10⁸ CFU / ml were prepared for the experiment. The bacterial suspensions were mixed with sNYC pH 5 or with sNYC containing H₂B₀B₁₁ formulated pH 5 and incubated anaerobically for 20.5 ha at 37°C. Petition 870250101940, dated 07 / 11 / 2025, pages 168 / 190 94 / 97 Next, the surviving bacteria were quantified by applying 2 μL of a series of 10-fold dilutions (lowest dilution 10-5) to chocolate / Schaedler agar plates and anaerobically incubating at 37°C for 48 h.
[00147] The H2B10B11 formulation eradicated the pathogens associated with bacterial vaginosis G. vaginalis, L. iners, M. mulieris, A. vaginae, and P. bivia (Fig. 6). This is an unexpected observation, since endolysin alone is not effective against non-Gardnerella strains, except to a lesser extent against L. iners (see FIG. 1B). As the results obtained here with Carbopol 974P are comparable to the results presented in Example 3 (Fig. 3), in which the formulation contained PAA, it can be concluded that poly(acrylic acid) and its pharmaceutical-grade crosslinked form (carbomer) lead to a synergistic extension of the lytic activity of endolysin. Furthermore, similarly to PM-477 formulated with PAA, H2B10B11 formulated with CP 974P does not harm beneficial L. crispatus (Fig. 6). Example 6 - The activity of H2B10B11 formulated with Carbopol is adjustable by modulating the salt content.
[00148] The potency of H2B10B11 alone or formulated with Carbopol 974P NF Polymer or Carbopol 971P NF Polymer (The Lubrizol Corporation) was tested against Gardnerella vaginalis in a planktonic environment for 90 minutes in NYC medium at pH 5.5 with normal (86 mM) or elevated NaCl concentration. Petition 870250101940, dated 07 / 11 / 2025, pp. 169 / 190 95 / 97 (345 mM) (FIG. 7). The formulation contained 10 μg / mL of H2B10B11 and 0.1% Carbopol with a final pH of 5.5. To produce the formulated treatment solution, 40 mg of CP 974P or CP 971P were added to 40 mL of NYC with normal or elevated NaCl concentration. After mixing, the pH was adjusted to pH 5.5 using 5 M NaOH. H2B10B11 was added at a final concentration of 10 μg / mL from a stock of 1.345 mg / mL in MES buffer pH 5.5.
[00149] Gardnerella was cultured on a Chocolate Agar plate anaerobically for 48 h at 37°C and then scraped from the plates using PBS. The bacterial suspensions were mixed with the respective medium containing H2B10B11, Carbopol, or a combination of both to produce a final bacterial OD of 0.1. The reaction plate was incubated anaerobically for 90 min at 37°C. Then, the surviving bacteria were quantified by applying 2 μL of a series of 10-fold dilutions (lowest dilution 10-5) onto Chocolate Agar plates and incubating anaerobically at 37°C for 48 h. Example 7 - Reduction of L. iners in vaginal swab samples from BV-positive women after 19 h of treatment.
[00150] Thirty vaginal swab samples from VB-positive women were treated for 19 h with 50 μg / mL of H2B10B11 or with 50 μg / mL of H2B10B11 formulated with 0.1% (w / v) CP 974P and 1% NaCl. For this, two vaginal swabs in medium Petition 870250101940, dated 07 / 11 / 2025, pp. 170 / 190 96 / 97 Amies (Copan 480CE) were pooled, 400 pL of NYC pH 5.5 + 10% horse serum were added, thoroughly mixed, and frozen. Treatment reactions were performed in a 96-well plate using 114 pL of the sample and the treatment solution in MES buffer pH 5.5. Reaction plates were statically incubated for 19 ha at 37°C under anaerobic conditions. Baseline (untreated samples) and treated samples were treated with PMAxx (Biotium), which intercalates into the DNA of dead cells, thus minimizing any qPCR signal from dead cells. Briefly, 4.5 pL of 50 μM PMAxx premix I were added to the cell pellets, incubated on ice for 15 min, and exposed to light in a PMALite LED photolysis device for 15 min. Treatment with PMAxx was repeated twice with 2.25 pL of 1 mM PMAxx premix II. The tubes were centrifuged for 8 min at 8000 rpm and the supernatants were discarded.The cell pellets were washed with saline solution and centrifuged for 10 min at 8000 rpm. Genomic DNA was extracted using the DNeasy 96 Blood & Tissue kit.
[00151] The viable load of L. iners was determined by viability qPCR using a pair of primers specific for L. iners. qPCR was performed on a LightCycler 480 (Roche) using EvaGreen® qPCR Supermix (Solis Biodyne) with 2 μK of DNA extracted by reaction in a total volume of 10 pL. The PCR conditions were as follows: initial denaturation Petition 870250101940, dated 07 / 11 / 2025, pages 171 / 190 97 / 97 at 95°C for 12 min, followed by 40 cycles of 15 at 95°C, 40 at 57°C and 30 at 72°C, followed by melting analysis between 55 and 95°C with a ramp rate of 2.5°C / s.
[00152] DNA copies / μL in treated samples subtracted by the charge in the respective untreated baseline samples are plotted over the charge in the baseline samples. Linear regression was performed between samples; the slope is shown in the graph. The slope reflects the overall reduction of L. iners in patient samples, i.e., a 99% reduction with formulated H2B10B11. Petition 870250101940, dated 07 / 11 / 2025, pp. 172 / 190
Claims
1 / 5 CLAIMS 1. Pharmaceutical composition, characterized in that it comprises an effective amount of an active agent and a pharmaceutically acceptable excipient, wherein said active agent is a polypeptide with lethal activity against Gardnerella and wherein said excipient is a polyacrylic acid polymer.
2. Pharmaceutical composition, according to claim 1, characterized in that said polypeptide is an endolysin with lethal activity against Gardnerella.
3. Pharmaceutical composition according to claim 2, characterized in that said endolysin comprises or consists of (i) an N-terminal catalytic domain, or a functional variant thereof; (ii) a C-terminal cell wall binding region, or a functional variant thereof, wherein the C-terminal cell wall binding region comprises or consists of at least one cell wall binding domain; and (iii) optionally a linking region between the N-terminal catalytic domain and the C-terminal cell wall binding region.
4. Pharmaceutical composition, according to any of the preceding claims, characterized by the fact that Petition 870250101940, dated 07 / 11 / 2025, page 173 / 190 2 / 5, said polypeptide is a polypeptide with at least 80% sequence identity with the amino acid sequence as provided in SEQ ID NO: 1 or SEQ ID NO: 37 and with lethal activity against Gardnerella.
5. Pharmaceutical composition, according to any of the preceding claims, characterized in that said polypeptide is a recombinant endolysin comprising the amino acid sequence as provided in SEQ ID NO: 1 or SEQ ID NO:
37.
6. Pharmaceutical composition, according to any of the preceding claims, characterized in that said polypeptide has lethal activity against Gardnerella vaginalis sensu stricto, Gardnerella leopoldii, Gardnerella piotii and / or Gardnerella swidsinskii, or any other species of the genus Gardnerella.
7. Pharmaceutical composition, according to any of the preceding claims, characterized in that said polypeptide has lethal activity against Lactobacillus iners.
8. Pharmaceutical composition, according to any of the preceding claims, characterized in that said polypeptide has no lethal activity against Lactobacilli crispatus, Lactobacilli gasseri, and / or Lactobacilli jensenii.
9. Pharmaceutical composition, according to any of the preceding claims, characterized in that said excipient is present in a concentration of about 0.01% to 10%, preferably about 0.1% to 1%, more preferably about 0.2% to 0.5%, and much more preferably about 0.25% or about 0.35%.
10. Pharmaceutical composition, according to any of the preceding claims, characterized in that the polyacrylic acid polymer is a cross-linked polyacrylic acid polymer or a carbomer.
11. Pharmaceutical composition, according to any of the preceding claims, characterized in that the combination of said active agent with said excipient enhances the pharmaceutical activity of said active agent.
12. Pharmaceutical composition, according to any of the preceding claims, characterized in that the composition additionally comprises a salt.
13. Pharmaceutical composition, according to claim 12, characterized in that the salt is sodium chloride (NaCl).
14. Pharmaceutical composition, according to any of the preceding claims, characterized in that said composition is suitable for intravaginal dispensing of the active agent.
15. Pharmaceutical composition, according to any of the preceding claims, characterized by being for use in the treatment of a bacterial infection in an individual, preferably where the bacterial infection is bacterial vaginosis.
16. Pharmaceutical composition, according to claim 15, characterized in that the individual has previously failed antibiotic treatment and / or the infectious bacteria are resistant to antibiotic treatment.
17. Pharmaceutical composition, according to claim 16, characterized in that the antibiotics said are nitroimidazoles and / or clindamycin.
18. Pharmaceutical composition, according to claim 16 or 17, characterized in that the antibiotics are Metronidazole, Tinidazole, Secnidazole, Clindamycin or any combination thereof.
19. Pharmaceutical composition, according to any one of claims 15 to 18, characterized in that the individual suffers from recurrent bacterial vaginosis, preferably when the individual has had two or more episodes of BV in 6 months or has had three or more episodes of BV in 12 months.
20. Pharmaceutical composition, according to any one of claims 15 to 19, characterized in that it is to be administered locally in the vagina of a woman Petition 870250101940, dated 07 / 11 / 2025, page 176 / 190 5 / 5 and / or on the glans penis, foreskin or urethral opening of a man.
21. Use of the pharmaceutical composition as defined in any one of claims 1 to 14, characterized by being in the manufacture of a medicament for the treatment or prevention of a bacterial infection, preferably bacterial vaginosis.
22. A method for treating or preventing a bacterial infection, preferably bacterial vaginosis, in an individual in need thereof, characterized in that it comprises administering to said individual a therapeutically effective amount of the pharmaceutical composition as defined in any one of claims 1 to 14. Petition 870250101940, dated 07 / 11 / 2025, pp. 177 / 190
